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Zusammenfassung 
 
Bei den dendritischen Zellen (DCs) handelt es sich um eine heterogene Population von 
antigenpräsentierenden Zellen, die zahlreiche Funktionen im Organismus übernehmen. Die 
genauen Mechanismen und Signalwege zur Entwicklung von dendritischen Zellen (DCs) sind 
jedoch bis heute weitestgehend unbekannt.  
 
Durch Untersuchungen der Expression von Transkriptionsfaktoren unter Anwendung eines 
Micro-Arrays konnte im Rahmen meiner Promotionsarbeit Gfi1 als ein entscheidender 
Transkriptionsfaktor in der GM-CSF-abhängigen Differenzierung von dendritischen Zellen 
(DCs) identifiziert werden. Wie Experimente mit Gfi1+/GFP-Knock-in-Mäusen, bei denen ein 
Gfi1-Allel durch die cDNA von GFP ersetzt ist, darlegten, wird Gfi1 sowohl in dendritischen 
Vorläuferzellen als auch in ausgereiften dendritischen Zellen (DCs) exprimiert. Im Vergleich 
dazu konnte in Gfi1-/--Knock-out-Mäusen eine globale Reduzierung von myeloiden und 
lymphoiden dendritischen Zellen (DCs) in allen lymphatischen Organen nachgewiesen 
werden, wohingegen die Anzahl an epidermalen Langerhans-Zellen erhöht war. Darüber 
hinaus zeigten die Gfi1-/--dendritischen Zellen (DCs) eine ausgeprägte Veränderung bezüglich 
des Phänotypes und der Funktion, was durch eine verringerte Expression von MHC-
Molekülen der Klasse II, eine ausbleibende Hochregulation von Kostimulationsfaktoren als 
Reaktion auf Stimulation und eine reduzierte Fähigkeit zur Stimulierung von spezifischen T-
Zell–Immunreaktionen veranschaulicht wurde. Im Gegensatz dazu wiesen die Gfi1-/--
dendritischen Zellen (DCs) ein erhöhtes Aktivierungprofil auf, welches sich in einer erhöhten 
Sekretion von IL-12 widerspiegelte.  
 
Desweiteren gelang es bei Untersuchungen zur Entwicklung von dendritischen Zellen (DCs) 
nicht, hämatopoetische Gfi1-/--Progenitorzellen in vitro durch Stimulierung mit den Zytokinen 
GM-CSF und Flt3L in dendritische Zellen (DCs) zu differenzieren. Dagegen konnte in diesen 
Experimenten eine Differenzierung zu Makrophagen beobachtet werden, welche durch 
morphologische Untersuchungen, Expressionsanalysen der Zelloberflächenmarker und 
funktionelle Analysen bestätigt werden konnte. Diese gewonnenen Erkenntnisse deuten 
darauf hin, daß der Transkriptionsfaktor Gfi1 eine entscheidende Rolle in der Modulation der 
Entwicklung von dendritischen Zellen (DCs) bzw. Makrophagen spielt.  
 
Untersuchungen des hämatopoetischen Chimärismus in bestrahlten kongenen Rezipienten im 
Rahmen von murinen Transplantationsversuchen konnten einen autonomen Zelleffekt und 
eine unersetzliche Funktion von Gfi1 in der Entwicklung von dendritischen Zellen belegen. 
Ferner konnte durch Überexpression von Gfi1 in Gfi1-/--Progenitorzellen mittels 
Durchführung eines retroviralen Gentransfers der Defekt einer ausbleibenden Entwicklung 
von dendritischen Zellen sowohl in vitro als auch in vivo behoben werden. 
 
Durch Proteinnachweise im Western blot und EMSA-Assay konnte nachgewiesen werden, 
daß die Unfähigkeit der hämatopoetischen Gfi1-/--Progenitorzellen zur Differenzierung in 
dendritische Zellen (DCs) mit einer Abnahme der STAT3-Aktivierung assoziiert ist. 
Zusammenfassend läßt sich festhalten, daß im Rahmen meiner Promotionsarbeit Gfi1 als 
entscheidender Transkriptionsfaktor für die Modulation der Entwicklung von dendritischen 
Zellen (DCs) bzw. Makrophagen identifiziert wurde und Gfi1 eine Schlüsselrolle in der 
Ausreifung sowie Aktivierung von dendritischen Zellen einnimmt. 
 
Schlagworte: dendritische Zellen, hämatopoetische Stammzellen, Transkriptionsfaktoren 
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Synopsis 
 
 
Dendritic cells (DCs) comprise heterogeneous and functionally diverse populations of antigen 
presenting cells. Their developmental pathways remain largely unknown. Using a 
transcriptional profiling approach, the present study identifies Gfi1 as a novel critical 
transcription factor in GM-CSF-dependent DC differentiation. Gfi1 is expressed in precursor 
and mature DCs. Gfi1-/- mice show a global reduction of myeloid and lymphoid DCs in all 
lymphoid organs whereas epidermal Langerhans cells are enhanced in number. Gfi1-/- DCs 
showed marked phenotypic and functional alterations, as exemplified by decreased MHC 
class II expression, absent upregulation of costimulatory molecules upon stimulation and 
reduced ability to stimulate specific T-cell responses. In contrast, Gfi1-/- DCs exhibited an 
increased activation profile as assessed by enhanced secretion of IL12. In vitro, Gfi1-/- 
hematopoietic progenitor cells were unable to develop into DCs in the presence of GM-CSF 
or Flt3L. Instead, they differentiated into macrophages, suggesting that Gfi1 is a critical 
modulator of DC versus macrophage development. Analysis of hematopoietic chimeras and 
retrovirus-reconstituted hematopoietic progenitor cells established a cell autonomous and non-
redundant role for Gfi1 in DC development. The developmental defect was associated with 
decreased STAT3 activation in hematopoietic progenitor cells. In conclusion, the present 
study for the first time reports Gfi1 as a critical transcription factor that controls DC versus 
macrophage development and dissociates DC maturation and –activation. 
 
Key words: Hematopoiesis, Dendritic cells, Transcription factors  
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Abbreviations 
 
 
APCs  Antigen presenting cells 
APC  Allo phycocyanin 
APS  Ammonium persulphate 
BM  Bone marrow 
C  Celcius 
CD  Clusters of differentiation 
CLP Common lymphoid progenitor 
CMP  Common myeloid progenitor 
CR1mix Chozhavendan Rathinam1 mix 
DCs  Dendritic cells 
DTT  Dithiothreitol 
EDTA  Ethylene diamine tetrasodium acetate 
ELISA Enzyme linked immunosorbent assay 
EMSA Electrophoretic mobility shift assay 
FACS  Fluorescence activated cell sorting 
FCS   Fetal calf serum 
FDCP  Factor dependent cell paterson 
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Flt3L  Fms like tyrosine kinase 4 Ligand 
FSc  Forward scatter 
Gfi1  Growth factor independent 1 
GFP  Green fluorescence protein 
GM-CSF Granulocyte macrophage colony stimulating factors 
GMFI  Geo mean fluorescence intensity 
GMFIi Geo mean fluorescence intensity index 
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IL  Interleukin 
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ICN  Intra cell domain region of Notch 1 
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Lin  Lineage 
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LPS  Lipo polysaccharide 
MHC  Major histo-compatibility complex 
Min  Minute 
MOI  Multiplicity of infection 
MLN  Mesenteric lymph node 
NaCl   Sodium chloride 
NH4Cl  Ammonium Chloride 
OT  Ova specific T cells 
PB   Peripheral Blood 
PBS   Phosphate buffered Saline 
PE  Phycoerythrin 
Per CP Peridinium chlorophyll protein 
PLN   Peripheral lymphnode 
PIAS  Protein inhibitor of activated STAT 
RBC  Red blood cells 
Sca  Stem cell antigen 
SCF  Stem cell factor 
SDS   Sodium do-decylsulphate 
SP  Spleen 
STAT  Signal transducers of activated transcripts 
TEMED N,N,N’N’-Tetramethylenediamine 
TGF  Transforming growth factor 
TNF  Tumor necrosis factor 
Tris  Tris-(hydroxymethyl)-aminomethane 
VSVG  Vesicular Stomatitis Virus Glycoprotein 
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1.Introduction  
1.1.  The Immune system  
The immune system is complex, intricate and interesting. It is composed of many 
interdependent cell types and specialized organs that collectively protect the body from 
bacterial, parasititic, fungal, viral infections and from the growth of tumor cells. Most of the 
cells of the immune system are derived from hematopoietic stem cells residing in the bone 
marrow. Bone marrow-derived stem cells differentiate into either mature cells of the immune 
system or into precursors of cells that migrate out of the bone marrow to continue their 
maturation in other anatomic compartments. Cells of the immune system include T cells, B 
cells, NK cells, mast cells, granulocytes, macrophages and dendritic cells. Many of these cell 
types have specialized functions. 
 
 
 
 
 
 
 
 
 
 
 
Adaptive (acquired) immunity refers to antigen-specific defense mechanisms that take several 
days to become protective and are designed to react with and remove a specific antigen. 
 
The organs of the immune system (Fig 1.1) have  
been categorized into 2 major subtypes; 
Primary organs include bone marrow and the thymus gland. 
Secondary organs include adenoids, tonsils, spleen, lymph  
nodes, Peyer's patches, and the appendix. 
Immunity is mediated by humoral and cellular effectors.  
The immune responses elicited by this complex network have 
been classified into innate immunity and adaptive immunity.  
Innate immunity refers to antigen-nonspecific  
defense mechanisms that a host uses immediately or  
within several hours after exposure to an antigen. 
 
Figure 1.1. Primary and secondary  
lymphoid organs of the immune system 
(Source: Steinman lab, Rockefeller university) 
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1.2 Hematopoietic stem cells  
Hematopoietic stem cells (HSCs) sustain blood production throughout life (Orkin SH, 2004). 
They are capable of self-renewal to maintain the HSC pool and have the ability for 
multilineage differentiation (Weissman IL, 2000). Multilineage hematopoiesis is maintained 
by a pool of hematopoietic stem cells (HSCs). HSCs comprise phenotypically and 
functionally defined long-term HSCs (LT-HSCs), short-term HSCs (ST-HSCs) and 
multipotent progenitors (MPPs)(Adolfsson et al, 2001; Weissman IL, 2001). This pool of 
cells can give rise to a series of intermediate lineage committed progenitors such as common 
lymphoid progenitors (CLPs) and common myeloid progenitor (CMPs) (Kondo et al, 1997; 
Akashi et al, 2000; Adolfsson et al, 2001; Christensen and Weissman, 2001). 
 
 
 
 
 
 
 
 
 
 
Further steps give rise to progenitors committed to the production of just one cell type (Fig. 
1.2). The steps of commitment can be correlated with changes in the expression of specific 
gene regulatory proteins, needed for the production of different subsets of blood cells. 
 
 
Figure 1.2. The paradigm of hematopoiesis 
CLPs give rise to all the different cell types 
of lymphoid origin including T, B, and NK 
cells (Kondo, 1997) plus dendritic cells 
(Reya et al, 2001). CMPs are capable of 
generating large numbers of all the different 
types of myeloid cells. Especially, they either 
give rise to megakaryocytes/erythrocytes or 
granuocyte/macrophage progenitors (Akashi, 
2000).  
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1.3 Dendritic cells 
DCs represent a key cell type of white blood cells that initiate and control both innate and 
adaptive immunity (Steinman RM, 1998). As sentinels, dendritic cells patrol the body seeking 
out foreign invaders, whether these invaders are bacteria, viruses, or dangerous toxins 
(Steinman RM, 1998) and hence they are referred as “conductors, pacemakers, or gatekeepers 
of the immune system”. DCs were first seen as Langerhans cells (LCs) in the skin in 1868. In 
1973 Steinman and Cohn recognized them as major cells of the immune system. Dendritic 
cells originate in the bone marrow and function as antigen presenting cells (APC). These cells 
are usually found in the structural compartment of the lymphoid organs such as the thymus, 
lymph nodes, spleen and the bone marrow. However, they are also found in the bloodstream, 
skin and other tissues of the body.  
  
 
Different DC subsets display unique sensitivity to certain chemokines (Banchereau J, 2000). 
Immature dendritic cells express a wide range of chemokine receptors such as CCR1, CCR2, 
CCR4, CCR5, CCR6, CXCR1, and CXCR4 in contrast to the mature dendritic cells that 
express only CCR7. The chemokines to which DCs respond include MIP-1a, MIP1-b, 
RANTES, MCP-3, MIP-5, MCPs, TARC, MDC, MIP-3a, MIP-3b, IL-8, SDF-1 and SLC.  
Figure 1.3.  Confocal microscope image 
of a human DC  
(Source: Karla Daniel, uiowa) 
Proliferating DC progenitors in the bone marrow give 
rise to precursor DCs that circulate in the blood. The 
precursors DCs in the blood reach the non-lymphoid
tissue, where they develop into immature DCs (Cella 
M, 1997; Banchereau et al, 2000) through a process 
called ‘migration’. This migration process is tightly 
controlled by chemokines produced upon local 
inflammation.  
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During their migration, DCs are involved in several adhesion events. For instance, E-
cadherin, uniquely expressed by LCs, permits through homotypic interactions, the residence 
of LCs in epidermis (Bell D, 1999; Jakob T, 1998). Ag encounter results in down regulation 
of E-Cadherin that allows LC migration out of the skin (Tang A, 1993). The release of 
collagenase of type IV by LCs may facilitate their migration though the basement membranes 
(Kobayashi Y, 1997). Likewise, human macrophage elastase is highly expressed by DCs and 
may thus contribute to their migration (Bancheraeu J, 2000). 
Immature DCs are very efficient in Ag capture and can use several pathways, such as 
macropinocytosis, receptor mediated endocytosis via C-type lectin receptors (mannose 
receptor, DEC205)(Engering AJ, 1997; jiang W, 1995; Sallusto F, 1995) or Fcg receptors 
types I and type II (Fanger, N.A., 1996), phagocytosis of particles such as latex beads 
(Matsuno, K., 1996); apoptotic and necrotic cell fragments (Albert, M.L., 1998); viruses and 
bacteria (Inaba, K., 1993) as well as intracellular parasites such as Leishmania major (Moll, 
H. 1993). DCs can also internalize the peptide loaded heatshock proteins gp96 and Hsp 70 
through presently unknown mechanisms (Arnold-Schild, D., 1999). 
 
 
 
 
 
 
Figure 1.4.  The life cycle of dendritic cells. 
Circulating Precursor DCs enter tissues as 
immature DCs. They can also directly 
encounter pathogens (e.g. viruses) that induce 
secretion of cytokines (e.g. IFNa), which in 
turn can activate eosinophils, macrophages 
(MF), and natural killer (NK) cells. After 
antigen capture, immature DCs migrate to lym-
phoid organs to allow selection of rare 
circulating antigen-specific lymphocytes. These 
activated T cells help DCs in terminal 
maturation, which allows lymphocyte 
expansion and differentiation. Helper T cells 
secrete cytokines, which permit activation of 
macrophages, NK cells, and eosinophils. B 
cells become activated after contact with T cells 
and DCs. It is believed that, after interaction 
with lymphocytes, DCs die by apoptosis.  
(Source : SRI biosciences division; Bancheraeu J, 2000) 
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The antigen/pathogen induces the immature DC to undergo phenotypic and functional 
changes that culminate in the complete transition from Ag-capturing cell to APC. DC 
maturation is intimately linked with their migration from peripheral tissue to the draining 
lymphoid organs. Several molecules including CD40, TNF-R, and IL-1R have been shown to 
activate DCs and to trigger their transition from immature to mature DCs. DC maturation is a 
continuous process initiated in the periphery upon Ag encounter and/or inflammatory 
cytokines and completed during the DC-T cell interaction. Numerous factors induce or 
regulate DC maturation including pathogen related molecules (LPS, bacterial DNA, dsRNA), 
the balance between proinflammatory and anti-inflammatory signals in the local micro 
environment (TNF, IL-1, IL-6, IL-10, TGF-b and prosaglandins) and T cell derived signals 
(Rescigno M, 1999; Akbari O, N., 1999; Hartmann G, 1999; Cella M, 1999). 
The maturation process is associated with several coordinated events such as loss of 
endocytic/phagocytic receptors, up regulation of co stimulatory molecules CD40, CD58, 
CD80 and CD86, change in morphology, shift in lysosomal compartments with down 
regulation of CD68 and upregulation of DC-lysosome associated proteins and most 
importantly, a change in class II MHC compartments.  
Morphological changes accompanying DC maturation include a loss of adhesive structures, 
cytoskeleton reorganization, and acquisition of high cellular motility (Winzler C, 1997). 
Even in the absence of invading pathogens, a fraction of the DCs seem to move around. The 
DCs that migrate in the steady state may replenish immature populations or may be on patrol 
to identify invaders. Not every pathogen or antigen induces a strong T cell response, but those 
that do can induce the mobilization and maturation of DCs (Steinman, 1998). 
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1.4 Functions of dendritic cells  
Dendritic cells are efficient stimulators and modulators of T (Steinman RM, 1998), NK and 
NK T cells (Ardavin C, 2003). In addition to stimulating responses against antigens, dendritic 
cells also produce tolerance to self antigens (Steinman RM, 2003).  
 
 
 
 
 
 
 
 
 
Formation of this MHC-peptide complex is critical to the activation of T cells. The DCs, with 
their antigen tags, travel to the lymph nodes, which are rich in T cells and present the antigen 
to the T cell, hence the term antigen-presenting cells (APCs). Once the resting, “naïve” T 
cells are activated, they trigger a complex immune response to either fight or tolerate these 
antigens. 
 DCs also induce tolerance to self-antigens by T cells during its development. This occurs in 
the thymus (central tolerance) by deletion of developing T cells and in lymphoid organs 
(peripheral tolerance) by induction of anergy or deletion of mature T cells. 
Dendritic cells are known to have major effects on B-cell growth and immunoglobulin 
secretion (Steinman RM, 1998). DCs activate and expand T –helper cells, which in turn 
induce B cell growth and antibody production. 
 
DCs use a variety of membrane 
receptors such as DEC205, MMR, FcR, 
Langerin, BDCA-2, DC-SIGN, ASGP-R 
to capture protein antigens (Steinman R 
2003), digest the antigens, and express 
these antigens on the surface membranes 
that are bound to MHC antigens to 
attract T cells (Steinman RM, 1998). 
Figure 1.5.  Antigen specific immune responses of 
lymphocytes are primarily initiated and governed by DCs. 
(Source: Steinman lab, Rockefeller university) 
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 Expression of IgA2 appears to be strictly dependent on a direct interaction between B cells 
and DCs (Fayette j et al, 1997). In addition, Follicular dendritic cells (FDCs) organize the 
primary B cell follicles. In the germinal centers the proliferating B cells (Centro blasts) 
undergo somatic mutation after which they stop dividing and wait to be triggered by an 
immune complex on FDCs. B cells that recognize this immune complex with high affinity 
process the antigen and present it as peptide-MHC complexes to antigen-specific T cells. This 
T-B cell interaction ensures the survival of high affinity B cells. In addition DCs also enhance 
differentiation of CD40-activated memory B cell towards IgG secreting cells (Dubois B, 
1998; Dubois B, 1997). DCs also help the differentiation of activated-naïve B cells into 
plasma cells (Banchereau J, 2000). 
DCs at different stages of differentiation can regulate effectors of immunity such as NK cells 
and NK T cells by both direct cell-cell interactions and indirect cytokine mediated 
interactions. Precursors of CD11c DCs may activate NK cells through the release of IFN-a; 
thereby leading to enhanced anti-viral and anti-tumor activity of NK cells (Cella M., 1997; 
Siegal FP, 1999;). DCs at later stages of development may regulate the activity of NK /NKT 
cells through the release of IL-12, IL-15, and IL-18 (Geldhof AB, 1998). 
 
 
Figure 1.6. Cell mediated immunity is an outcome of an 
interaction between DCs and other lymphocytes. 
(Source: Steinman lab, Rockefeller university) 
Naïve B cells respond uniquely to the 
interstitial non-LC type of DCs (Caux C 
et al, 1997; Dubios B et al, 1997), and 
by secretion of soluble factors (Dubios., 
1997), including IL-12, DCs also 
orchestrate immunoglobulin class 
switching of T cell-activated B cells. 
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1.5 Subtypes of dendritic cells  
 To date several subpopulations of DCs have been identified and described based on the 
expression of cell surface markers, functional characteristics and anatomical localisation. 
Historically, both human and mouse DCs have been named according to their appearance and 
distribution in the body as: Langerhans, Interstitial, Blood, Veiled, Lymphoid or 
Interdigitating dendritic cells that belong to Epidermis, Dermis or Interstitium, Circulatory 
System, Afferent Lymph and Lymph Nodes respectively. During the past decade, DCs were 
further classified by lineage, by maturation stage, by functional and phenotypic characteristics 
of these stages, and by mechanisms involved in migration and function (Cella M et al, 1997; 
Austyn J, 1996). More recently dendritic cells are classified into various subcategories based 
on the expression of defined cell surface molecules. 
Human: In contrast to the many studies on mouse DCs, there are relatively few studies on 
mature human DCs freshly isolated from tissue (Shortman K, 2002). Blood is the only readily 
available source and is a major source of immature dendritic cells (iDCs) and pDCs. Human 
blood dendritic cells are heterogeneous in their expression of a range of markers, but many of 
these reflect differences in the maturation and activation states of DCs rather than separate 
sublineages. (Hart DN, 1997). In few cases human DCs have been isolated from lymphoid 
Figure 1.7.  Multifarious functions of dendritic cells. 
(Source: Steinman lab, Rockefeller university)  
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tissues and analysed for the presence of different subtypes. Splenic and tonsilar DCs show 
heterogeneity in the expression of CD4, CD11b and CD11c indicating a level of complexity 
resembling mouse splenic DCs (Shortman K, 2002). However the relationship between these 
subtypes is not clear. Most human thymic DCs are CD11c+ CD11b-CD45Rlow and lack 
myeloid markers and hence resemble mouse thymic CD8+ DCs. A minority of human thymic 
DCs are CD11chiCD11b+CD45Rhi and express many myeloid markers and thus resemble 
mouse CD8a - DCs (Vandenabeele S et al, 2001; Bendriss VN et al, 2001).  In addition most 
of the insights about human DC subsets have come from in vitro studies (Shortman K, 2003). 
The in vitro differentiation of human CD34+ stem cells gives rise to 3 independent lineages of 
DCs (Caux C et al, 1996; Caux C et al, 1996). One of the lineages, originating in the presence 
of TGFb, resembles Langerhans cells; in that they have Birbeck granules and expresses the 
Langerhans-associated antigens (Lag) langerin and E-Cadherin. The second lineage resembles 
intestinal DCs, lacking birbeck granules but expresses CD9, CD68 and coagulation factor 
XIIIa. The third lineage produces dendritic cells from the lymphoid-restricted precursors with 
in the CD34 population (Galy A et al, 1995). Additional studies on human monocytes have 
revealed two more intermediate subtypes of DCs; pDC1 and pDC2. pDC1 develop in the 
presence of GM-CSF and IL-4 (Sallusto F et al, 1994; Bender A et al, 1996; Romani N et al, 
1996). They can be identified by expression of surface markers CD14-CD38+ CD86+MHC-
IIhi. In contrast, pDC2 precursors, which develop in the presence of IL-3 and CD40L, 
differentiate into interferon a/ß–producing plasmocytoid cells (Rissoan MC et al, 1999; 
Grouard G et al, 1997) that can be recognised by their plasma-cell-like morphology and their 
unique surface phenotype CD4+IL-3-receptor+CD11c-. In spite of scattered reports on DC 
subtypes, a comprehensive classification system of human dendritic cell subtypes remains to 
be established. 
Mouse: Murine DCs can be classified into many subtypes based on their expression of 
specific surface markers. Irrespective of the subtypes all mature dendritic cells express 
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CD11c- ‘the hallmark of dendritic cells’. Ken Shortman and (2002) Yong-Jun-Liu have 
classified murine dendritic cells into 5 major categories based on their expression for surface 
markers CD4, CD8a, CD11b and CD205 in addition to CD11c in the lymphoid tissues of 
uninfected laboratory mice. According to this system of categorisation, the mouse spleen 
possesses three subtypes of CD11c positive dendritic cells: CD4-CD8a+, CD4-CD8a- and 
CD4-CD8a-DCs. The CD4-CD8a+ DC subtype, which is CD205+CD11b-, is also found in 
moderate levels in LNs, but is the dominant subtype of thymic DCs.  In addition, lymph nodes 
harbour another two novel DC subtypes that are defined by CD4-CD8a-CD11b+CD205int, 
which is believed to be the mature form of tissue interstitial DCs, and CD4-
CD8alowCD205highCD11b+ langerinhigh, which is believed to be the mature form of 
Langerhans cells.  
Based on an alternative system of categorisation proposed by Ardavin (Ardavin C, 2003), 
mouse dendritic cells are classified into six main subpopulations. In this framework, murine 
DCs in the lymphoid tissues can be divided into CD8a- and CD8a+ subpopulations. CD8a- 
DCs can further be subdivided into CD4-CD8a- and CD4+CD8a- subsets. In addition, DCs 
that express intermediate levels of CD8a (CD8aint) constitute a lymph node specific subset of 
DCs. In peripheral lymph nodes, CD8aint DCs seem to derive from epidermal Langerhans 
cells and in mesenteric lymph node they seem to originate in the intestinal lamina propria. 
Finally, a peculiar DC subtype that is been defined by the expression of B220 (a counterpart 
of human plasmacytoid DCs) is found in all lymphoid organs of the mouse. In spite of the 
phenomenological description of DC categories based on the expression of cell surface 
markers, a uniform and unequivocally acccepted classification system of murine dendritic 
cells is still lacking. 
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1.6 Developmental origin of Dendritic Cells  
Despite the phenotypic characterisation of diverse DC subpopulations, their developmental 
pathways of differentiation from hematopoietic stem cells (HSCs) remain poorly defined 
(Ardavin C, 2003). DCs were originally thought to be derived from myeloid precursors due to 
their functional, phenotypic and morphological similarities with macrophages. Early concepts 
postulated the existence of CD8a+ lymphoid DCs and CD8a- myeloid DCs, originating from 
common myeloid progenitors and common lymphoid progenitors respectively (Vremec, 1992; 
Anjuere, 1999; Wu, 1996). However, this conceptual dichotomy has been challenged when it 
was shown that myeloid progenitor cells can give rise to “lymphoid” DCs and that lymphoid 
progenitor cells can give rise to “myeloid” DCs (Martin, 2000; Manz, 2001; Traver, 2000). 
However, the finding that the differentiation of CD8a+ and CD8a- DCs require different 
cytokines and involves different transcription factors indicates that their developmental 
pathways might differ (Wu, 1998; Guerriero, 2000; Saunders, 1996). Recent findings that are 
derived mainly from in vivo studies of DC development have shown that differentiation of 
DC is more complex than expected. 
 
1.7 Dendritic cell precursors 
The definition of DC committed precursors has remained elusive in both human and mice.  
Human peripheral blood monocytes harbour at least 2 distinct DC precursors; pDC1 (CD14-
CD38+ CD86+ MHC-II high) which differentiate into DC1, and pDC2 (CD45RahiCD11cloIL-
3Rhi) that differentiate into DC2 or plasmocytoid dendritic cells (Rissoan MC et al, 1999; 
Grouard G et al, 1997; Res P.C. et al, 1999; Spits H et al, 2000). The first description of a DC 
restricted precursor population in mouse blood was reported by Ardavin et al (2000). These 
cells were described as CD11c+ MHCClassII- and were able to completely reconstitute splenic 
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CD8a- and CD8a+ and plasmocytoid B220+ DC subpopulations. However, these cells are 
devoid of lymphoid or myeloid differentiation potential (Martinez et al, 2002). 
Recently, another mouse DC progenitor population has been discovered in the bone marrow 
(Amico et al, 2003). These progenitors are defined by the cell surface expression profile Lin-
Sca1-c-kit+Flt3+ and appear to be the earliest precursors of all DC subtypes irrespective of 
their myeloid or lymphoid orientation. These studies are important since it is now possible to 
identify distinct precursor cells of the DC lineage, a prerequisite to define distinct 
developmental steps of DC development.  
 
1.8 Cytokine regulation of dendritic cell development  
Cytokines are diverse and potent chemical messengers secreted by specialized cells such as T 
cells, B cells, macrophages, dendritic cells, epithelial cells, mesenchymal cells and neuronal 
cells. Cytokines and chemokines are pleiotropic, redundant, and multifunctional in nature. 
Upon binding to specific receptors on target cells, cytokines recruit many other cells and 
substances to the field of action. Cytokines encourage cell growth, promote cell activation, 
direct cellular traffic, and destroy target cells—including cancer cells. Because they serve as a 
messenger between leukocytes, many cytokines are also known as interleukins.  
Hematopoiesis is largely controlled by the effects of specific cytokines in vitro. Accordingly, 
DC differentiation from different hematopoietic precursors requires a number of defined 
cytokines (Ardavin C, 2001). Initially, these cytokine combinations (see below) were defined 
on the basis of in vitro differentiation studies using hematopoietic precursors cells. Additional 
information concerning the involvement of cytokines in the differentiation of DCs arises from 
genetically deficient mice. These experimental data indicate that some cytokines appear to 
have a dispensable role, whereas others are strictly required for the generation of DCs. The 
most relevant cytokines involved in the differentiation of DCs are considered. 
 22 
GM-CSF appears to be required for the in vitro differentiation of DCs from BM and blood 
progenitors, but not from thymic progenitors (Inaba K et al, 1992).  Nevertheless, the 
generation of DCs from BM Lin- cells in the absence of GM-CSF was reported (Brasel K et 
al, 2000). It should be noted that GM-CSF or GM-CSFR deficient mice display normal 
development of DCs (Vermac D et al, 1997). 
TNF-a employed in most mouse and human DC and LC differentiation assays from BM 
precursors, and has been proposed to be crucial cytokine for the generation of DCs from 
human CD34+ precursors (Caux C et al, 1992). However no defects in the differentiation of 
DCs have been reported in TNF-a or TNFRI deficient mice (Zhang Y et al, 1997) suggesting 
that TNF-a is not a necessary factor in DC development in vivo. 
Flt3L has been demonstrated to have strong differentiation-promoting potential for mouse 
and human DCs, both in vivo and in vitro (Brasel K et al, 2000; Maraskovsky E et al, 1996; 
Maraskovsky E et al, 2000; Curti A et al, 2001). Consequently Flt3L deficient mice displayed 
important defects in the differentiation of DCs (Mc kenna HJ et al 2000). In addition, Flt3L 
has been claimed to increase the in vitro survival of DC precursors and selectively favor their 
differentiation (Curti A et al, 2001). Thus, Flt3L appears to play an essential role in the 
differentiation of DCs under both in vitro and in vivo conditions.  
IL-4 has been shown to be a key cytokine for inducing the differentiation of DCs from human 
monocytes, and interestingly, it has been shown that IL-4 exerts an inhibitory function on 
macrophage differentiation (Romani N et al, 1994). It has been shown that IL-4 allows the 
generation of murine DCs from bone marrow cells, in combination with GM-CSF 
(Mayordomo JI et al, 1995). 
TGF-ß is an important cytokine for in vitro differentiation of LCs and required to achieve a 
complete and/or more physiological differentiation of Langerhans cells. Importantly, the skin 
of TGF-b deficient mice is devoid of epidermal LCs (Borkowski T A et al, 1996).  
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In addition, CD40L and IL-3 have shown to promote differentiation of DC2 cells from pDC2 
precursors (Rissoan MC et al, 1999; Grouard G et al, 1997). Different cytokines or 
combinations of cytokines are necessary for the development of the various subsets or 
phenotypes of DCs. Some cytokines, such as GM-CSF, have been identified to promote 
growth, maturation and migration of DCs both in vitro and in vivo. Ultimately, cytokine 
induced signalling leads to a change in the transcriptional profile of progenitor cells, including 
a modified expression pattern of transcription factors.  
 
1.9 Transcription factors and dendritic cell development  
The lineage fate of hematopoietic progenitor cells is controlled by an orchestrated expression 
pattern of transcription factors (Orkin S, 2000), yet the molecular mechanisms governing the 
diversification of dendritic cell progenitor cells remain largely unknown. The analysis of 
gene-targeted mice has revealed the functional importance of a few critical transcription 
factors for DC development. Moreover the analysis of DC subpopulations in mice deficient 
for transcription factors involved in myeloid and lymphoid development was undertaken to 
address the derivation of DC lineages. Few critical transcription factors controlling DC 
development have been identified and will be discussed in some detail: 
Ikaros: Ikaros represents a transcription factor of the zinc finger family and was originally 
identified as a factor critical for T cell development (Kaufmann et al, 2003) In addition to the 
T cell phenotype, Mice homozygous for a dominant negative mutation in the Ikaros gene 
(Ikaros DN-/-) displayed a complete lack of all thymic and splenic DCs (Wu et al., 1997). 
Even though a profound deficiency is observed in the lymphoid DC lineages, epidermal LCs 
are being generated in these knockout mice. Mice with an Ikaros null mutation (Ikaros C-/-) 
display less severe defects in lymphoid development, having reduced differentiation of 
CD8a+ DCs in the thymus and spleen, more surprisingly the 8a- DCs were completely absent 
in the spleen. 
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Rel-B: Rel-B is a member of NF-kB/Rel family. Rel-B gene targeted mutant mice were 
reported to lack DC in thymus and spleen and to have impaired antigen presenting cell 
function (Wu L et al, 1998). In these mice the CD8a+ DC appear to be normal. However, 
there is a lack of CD8a- DCs in the spleen. The number of epidermal Langerhans cells 
remains unaffected. 
PU.1: PU.1 is a member of the ets family of DNA binding proteins and is expressed only in 
the hematopoietic cells.  PU.1 deficient mice (Guerriero A et al, 2000) produce functional 
CD8a+ DCs but lack CD8a- DCs. PU.1 deficient mouse hematopoietic progenitor cells fail to 
generate DCs in culture. Thymic DCs couldn’t be detected in the PU.1 deficient mice. 
However the dendritic cells appear to be functional. 
ICSBP:  Interferon consensus sequence binding protein (ICSBP) is a transcription factor that 
belongs to the interferon regulatory factors (IRF) family. The expression of ICSBP is 
restricted to myeloid and lymphoid cell lineages. ICSBP deficient mice lack interferon-
producing cells (IPC) in all lymphoid organs (Schiavoni G et al, 2002). A marked reduction of 
CD8a+ cells in all lymphoid organs was noticed. Moreover, an altered response of CD8a+ 
cells to activation signals is noticed. ICSBP deficient mice exhibited a reduced frequency of 
LCs and a delayed mobility of DCs from skin to lymph nodes. Bone marrow derived DCs 
exhibited an immature phenotype and showed a severe reduction of IL-12 production. 
Id2: Id proteins are a group of proteins (1-4) that possess a highly conserved helix-loop-helix 
(HLH) domain. Id2 knockout mice were deficient in CD8a+ DCs and showed a complete 
absence of epidermal Langerhans cells (Hacker C et al, 2003). 
STAT3:  STAT3 is a cytoplasmic transcription factor that is a key mediator of cytokine and 
growth factor signalling pathways. Mice carrying a conditional deletion of the STAT3 gene in 
the hematopoietic cells showed profound defects in the DC compartments (Laouar Y et al, 
2003). STAT3 deficient mice showed a complete lack of CD8a+ DCs and an abrogated DC 
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development in all the lymphoid organs. Flt3L-mediated in vitro DC differentiation of STAT3 
deficient bone marrow cells failed to generate plasmocytoid (CD11c+ CD11b-) DCs although 
myeloid DCs (CD11c+ CD11b+) DCs could be generated. 
P50 and RelA: P50 and RelA are the subunits of the transcription factor NFkB that play an 
important role in inflammatory and immune response genes. Mice deficient for both P50 and 
RelA showed dramatically impaired DC development (Quaaz F et al, 2002). They showed a 
complete lack of splenic DCs. Both CD8a+ and CD8a- subtypes are reduced and cells that 
exhibit DC morphology were completely absent. 
IRF-2: IRF-2 is a transcriptional repressor that was identified as a regulator of the type I 
interferon system. Severe reduction of CD4+CD11b+ DCs and epidermal langerhans cells was 
noticed even though the CD8a+ DC compartment remained unaffected (Ichikawa E et al, 
2004). Furthermore, reduced frequencies of the generation of mature DCs from IRF-2 
deficient BM in vitro were noticed. 
IRF-4: IFN regulatory factor 4 is a transcription factors that plays an essential role in the 
homeostasis and function of immune systems. Mice deficient for IRF4 show a severe 
reduction of CD4+CD8a- DCs in spleen and the generation of CD11b+ DCs from bone 
marrow of IRF-4 -/- mice was severely impaired (Suzuki S et al, 2004). 
Although the availability of the gene knockout mice mentioned above has greatly enhanced 
our understanding of transcription factor controlled DC development, a comprehensive view 
integrating all decisive factors is still lacking. 
 
1.10 Growth-factor-independent-1 
The gene locus encoding the Growth-factor-independent-1 (Gfi1) protein was discovered in a 
screen for moloney murine leukaemia virus (MoMuLV) proviral integration site in NB2 rat 
lymphoma cells and in T-lymphoid tumors (Gilks et al, 1993; Schmidt et al, 1996; Zöring et 
al, 1996; Scheijen et al, 1997). The Gfi1 gene encodes a 55-kDa nuclear transcription factor, 
 26 
which harbours six carboxy-terminal C2-H2 zinc-finger domains and a characteristic N-
terminal 20 amino acid stretch termed ‘SNAG’ domain, which is well conserved between 
Gfi1 and the proteins Snail and Slug (Grimes et al, 1996; Zweidler-Mckay et al, 1996). 
Reporter gene experiments suggested a transcriptional repressor activity of Gfi1 that depends 
on the DNA binding activity and on intact SNAG domain (Grimes et al, 1996; Zwidler-
McKay et al 1996). An alternative activity of Gfi1 has been discovered through its interaction 
with PIAS (Protein inhibitor of activated STAT) 3, which is an inhibitor of signal transducers 
and activators of transcription (STAT) 3 suggesting a role of Gfi1 in a set of specific cytokine 
signalling pathways (Rodel et al 2000). 
Early studies revealed a key role of Gfi1 in lymphomagenesis and lymphopoiesis (Gilks et al 
1993; Grimes et al, 1996; Schmidt et al, 1998). Gfi1 can act as a dominant oncogene when 
over expressed, and cooperates strongly with other oncoproteins such as Pim1 (a cytoplasmic 
serine/threonine kinase) or Myc (an HLH-LZ transcription factor) in accelerating progression 
of T-cell lymphomagenesis (Zoring et al, 1996; Scheijen et al, 1997; Schmidt et al, 1998). 
Moreover Gfi1 regulates IL-4/STAT6-dependent Th2 proliferation (Zhu et al, 2002), and IL-
6/STAT3-mediated proliferative responses to antigenic stimulation (Rodel et al, 2000). 
Later studies showed that Gfi1 is also expressed in granulocytes and in activated macrophages 
(Karsunky et al, 2002) and in distinct areas of nervous system, most prominently in the inner 
ear hair cells (Wallis et al, 2003). In the immune system, ablation of Gfi1 by gene targeting in 
mice caused defects in early T-cell maturation (Yücel et al, 2003) and led to severe 
neutropenia and a profound monocytosis (Karsunky et al, 2002; Hock et al, 2003).   Recently 
it has been shown that the loss of Gfi1 affects the frequencies of HSCs and progenitors, in 
particular ST- and LT-HSCs and CLPs but leaves MEPs unaltered and suggested a role of 
Gfi1 in regulating the development of distinct myeloid and lymphoid progenitor cell 
populations and HSCs (Zeng et al, 2004). In additon, the importance of Gfi1 in restricting 
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HSC proliferation and in preserving HSC functional integrity has also been reported (Hock et 
al, 2004).   
The current study aimed to use an in vitro DC differentiation system for transcriptional 
profiling using microarray analysis and to determine the transcription factor repertoire 
expressed during the differentiation program of the DCs. The transcriptional repressor Gfi1 
was strongly upregulated in DCs both in vitro and in vivo. Characterisation of Gfi1-/- mice 
demonstrated that Gfi1 was crucial for the development of distinct subtypes of dendritic cells. 
Gfi1-/- mice showed both quantitative and qualitative abnormalities in almost all dendritic cell 
compartments with an exception of langerhans cells. The ablation of DC development in vitro 
by the Gfi1 deficient cells is correlated with the defective STAT3 signaling.   
Hence, the results of this study unravel a previously unrecognized important role of Gfi1 in 
the regulation of development and activation of dendritic cells and in the lineage decision 
between dendritic cells and macrophages. 
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2. Aims of the  proposed study  
 
Hypothesis: 
The fundamental hypothesis guiding my studies was that an analysis of upregulated 
transcription factors during early steps of GM-CSF-dependent DC maturation might help to 
elucidate critical master regulators controlling DC differentiation.  
 
My thesis project had the following specific aims:  
 
1. To analyze murine hematopoietic progenitor cell lines for their potential to 
differentiate into dendritic cells. 
2. To undertake a genome wide screen to identify differentially expressed genes during 
early steps of GM-CSF mediated DC differentiation in vitro. 
3. To study the role of upregulated transcription factors in available transgenic mice. 
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3. Materials and Methods 
3.1 Buffers and Media 
PBS: 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.2  
PBS, BSA(0.5%) 
PBS, FCS(2%) 
RPMI-medium: RPMI, containing 10% FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 
0.3 mg/ml glutamine, and 10 mM 2- Mercaptoethanol 
IMDM-medium: IMDM, containing 10% FCS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 
0.3 mg/ml glutamine, and 10 mM 2-Mercaptoethanol 
DMEM-medium: DMEM, containing 10% FCS, 100 U/ml penicillin, 0.1 mg/ml 
streptomycin, 0.3 mg/ml glutamine 
RBC lysis buffer: 7 mM Tris, 140 mM NH4Cl, pH 7.65  
Agarose gel buffer: 89 mM Tris base, 89 mM boric acid, 2 mM EDTA 
RPIA buffer: 10 mM Tris (pH 7.5), 150 mM Nacl, 1 mM EDTA, 1% NP-40, 0.5% Na-
Deoxycholate, 0.1% SDS, PIC (70 uL/mL) 
Protease inhibitor cocktail (PIC): 104 mM AEBSF, 0.08 mM Aprotinin, 2 mM leupeptin, 4 
mM Bestatin, 1.5 mM Pepstatin A, 1.4 mM E-64  
Laemmli electrophoresis buffer:  50 mM Tris-HCl, 0.196 M glycine (pH 8.3), 20% 
methanol  
SDS PAGE buffer: 25 mM Tris, 192 mM glycine, 0.1% SDS 
Transfer buffer (Western): 192 mM glycine, 25 mM Tris 
Blocking buffers (Western): PBS-T, 5% non-fat milk 
Wash buffer (Western): PBS, 0.1% Tween-20 
Coomassie stain solution: 50% Methanol, 7% Acetic acid, 0.1% Coomassie 
Destain solution(Coomassie): 50% Methanol, 7% Acetic acid 
Ponceau stain solution: 0.1% Ponceau S, 5% Acetic acid 
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Hypotonic buffer (EMSA): 20 mM HEPES (pH 7.6), 10 mM KCl, 1 mM MgCl2, 20% 
Glycerin, 0.1% Triton X-100, 0.5 mM DTT, 1 mM Na-Orthovanadate, PIC (70 uL/mL) 
Hypertonic buffer (EMSA): 20 mM HEPES (pH 7.9), 400 mM NaCl, 1 mM EDTA, 20% 
Glycerin, 0.1% Triton X-100, 1 mM DTT, 1 mM Na-Orthovanadate, PIC (70 uL/mL) 
Shift buffer (EMSA): 10 mM HEPES (pH 7.9), 50 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 
5% Glycerine, 0.1% NP-40, 5 mM Na-Orthovanadate 
EMSA running buffer: 44 mM Tris base, 44 mM Boric acid, 1 mM EDTA 
ELISA coating buffer: 0.2 M NaPo4 (pH6.5) 
Wash buffer(ELISA):  0.05% Tween?20 in PBS, pH 7.2 - 7.4. 
Reagent diluent(ELISA): 1% BSA in PBS, pH 7.2 - 7.4, 0.2 mm filtered. 
Stop solution(ELISA): 2 N H2SO4. 
 
3.2 Instruments 
       
FACS Calibur (BD-Pharmingen, SD, CA) 
FACScan (BD-Pharmingen, SD, CA) 
Cell sorter Moflow (DAKO Cytomation, Denmark) 
AutoMACS (Miltenyi-Biotec, Germany) 
ELISA reader (Molecular Devices, MWG-Biotech, Germany) 
Phospho imager (Fuji Image, japan) 
Kodak imaging station (Kodak, Germany) 
Microscope Zeiss (zeiss, Germany) 
Agarose gel chamber (Biorad, Germany) 
Spectrophotometer (Eppendorf, Germany) 
Mastercycler gradient (Eppendorf, Germany) 
Light cycler (Roche, Germany) 
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Western blot apparatus (Biorad, Germany) 
Centrifuge (Sorval; Eppendorf, Germany) 
 
3.3 Methods 
 
Mice: All mice were maintained under specific pathogen free conditions in the central animal 
facility at Hannover Medical School. Age and sex matched transgenic Gfi1-/- and Gfi1GFP/+ 
mice (Karsunky et al., 2002b; Yucel et al., 2004) were used at four to eight weeks of age. 
C57BL/6 Ly5.1-Pep3b (CD45.1) mice were purchased from Jackson Labs (Bar Harbor, 
Maine, USA) and used at 8-12 weeks of age. OT-I and OT-II Rag-/- mice were kindly 
provided by T. Greten, Hannover Medical School.  
 
Cells and cell culture:  FDCP-mix cells were differentiated into DCs according to a 
previously published protocol (Schroeder et al., 2000). In brief, FDCP-mix cells were cultured 
in the presence of r-mGM-CSF (5 ng/mL) and 1% of WEHI supernatant for 7 days (as a 
source of m-IL3) in IMDM medium supplemented with 20% horse serum, 2 mM L-
Glutamine, 1% Penicillin and Streptomycin (all from Gibco,  Karlsruhe, Germany). To 
generate bone marrow derived dendritic cells, bone marrow cells were depleted of Gr1+, 
Mac1+, CD3+, TER119+ and B220+ cells using magnetic beads (Miltenyi Biotech, Bergisch 
Gladbach Germany). Lineage-depleted progenitor cells were cultured in IMDM, 10% FCS, 2 
mM L-Glutamine, 1% Penicillin-Streptomycin, 1 mM Non-essential amino acids, 5 x 10-5 M 
2-mercaptoethanol for 7 days in the presence of recombinant murine GM-CSF and IL-4 
(Sigma, Munich, Germany), or recombinant human Flt3L (Peprotech, Rocky Hill, NJ). In 
some confirmatory experiments, supernatants of the engineered cell lines EL4-GM-CSF and 
EL4-IL4 were used as cytokine source. 
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For in vivo DC analysis, lymphoid organs were cut into small pieces, treated with collagenase 
D (Boehringer, Mannheim,Germany) for 30 min at 37 °C, gently meshed and washed with 
PBS containing 50 µg/mL Dnase I (Roche, Mannheim, Germany) and 2 mM EDTA. In some 
experiments, splenic DCs were purified by labelling splenic single cell suspensions with anti-
CD11c microbeads (N418) and subsequent enrichment by immunomagnetic columns 
(Miltenyi Biotech). For retroviral gene transfer, Sca-1+lin- cells were cultured in IMDM 
containing 10% FCS, 2 mM L-Glutamine, 1% Penicillin-Streptomycin, 1 mM Non-essential 
amino acids, 10 ng/ml rm-IL3, 10 ng/ml rm-IL6, 50 ng/ml rm-SCF, 50 ng/ml rh-Flt3L and 25 
ng/ml h-TPO (all from Peprotech, Rocky Hill, NJ). 
For T cell proliferation studies, Gfi1-/- and Gfi1+/+  splenic DCs were pulsed with 1 µg/ml Ova 
peptide SIINFEKL and Ova323-339, respectively,  irradiated (30 Gy) and incubated with 105  
lymphocytes from either OT-I or OT-II mice in a 96 well plate. Allogeneic T cell proliferation 
was performed using 105 lymph node cells obtained from Balb/C mice as responder cells and 
irradiated (30 Gy) bone-marrow-derived cells as stimulator cells. On day 3 of culture, the 
cells were pulsed with 1 µCi 3H-Thymidine for 16 hours. Incorporated 3H-Thymidine was 
quantified by scintillation counting. 
 
Flow cytometry, immunofluorescence and ELISA: Single cell suspensions were analysed 
by flow cytometry using a FACS-Calibur and CELLQuest software (BD Biosciences, San 
Jose, CA). In some experiments, cell sorting of Sca-1+lin- and Lin-Sca-1+c-kit+ cells was 
performed using a Moflo cell sorter (DAKO Cytomation, Glostrup, Denmark).  
The following monoclonal antibodies (all from BD Pharmingen, San Diego, CA except noted 
otherwise) were used: CD3e-FITC & -biotin, CD4-FITC & -PE,  CD8a-FITC, -PE & -PerCP, 
CD11b-FITC & -biotin, CD11c-PE & -APC, CD34-FITC, CD40-FITC & -PE, CD45.1-
biotin, CD45.2-FITC, CD80-FITC & -PE , CD86-FITC & -PE, CD117-PE & -APC, B220-
FITC, -PE & -biotin, H2-kb-FITC, I-Ab-PE, TER119-biotin, GR-1-FITC & -biotin, IL7Ra-
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biotin, FcRg-PE, Sca-1-PE, Flt3-PE, CD45.2-FITC, V 2(B20.1)-biotin, anti-mouse-STAT3, 
goat-anti-mouse-IgG-HRP, F4/80-FITC (Zymed laboratories, South San Francisco, CA), I-
Ab-APC (eBiosciences, San Diego, CA). In all experiments, cells were also stained with 
corresponding isotype-matched monoclonal antibodies. Cells reacted with biotinylated 
monoclonal antibodies were incubated with fluorochrome-conjugated streptavidin-PerCP or 
streptavidin-APC (BD Pharmingen). For in vivo DC maturation studies, a-CD40 (FGK-45) 
monoclonal antibodies were purified from the hybridoma cell line FGK-45 (kindly provided 
by A. Rolink). All fluorescence intensity plots are shown in log scales.  
To enumerate epidermal Langerhans cells, ears were split into dorsal and ventral halves and 
incubated in PBS with 20 mM EDTA for 2.5 hours. Epidermal sheets were fixed, blocked, 
and  stained with APC-conjugated anti-I-Ab monoclonal antibodies. LC density was 
determined by fluorescence microscopy using a micrometer grid (field size: 0.25 mm2). 
For cytokine assays, purified splenic DCs were stimulated in a 96 well plate with 10 ng/ml 
LPS, 100 ng/ml TNF-a (both from Sigma Aldrich) or 10 µM CpG-DNA (TibMolBiol, Berlin, 
Germany) for 48 hrs. The supernatants were harvested and IL-12p70 levels were measured 
using mouse IL-12p70 ELISA set (BD Pharmingen). 
 
Microscopy: Phase contrast images of DCs were taken using a Zeiss Axiovert 200 
microscope at an original magnification of x 100. Photodocumentation was performed using 
an ORCA-2 camera system and Open labT software. Giemsa-stained DCs were observed 
using a Zeiss Axioplan 2 microscope (original magnification x 100). 
 
Protein assays: Extraction of nuclear and cytoplasmic proteins was carried out using standard 
protocols. Briefly, cells were harvested and  lysed in hypotonic buffer containing 20 mM 
Hepes (pH 7.6), 10 mM KCl, 1 mM MgCl2,  2% glycerin, 0.1% Triton-X100, 0.5 mM DTT 
(Roche), 1 mM Pefabloc (Roche), 1 mM sodium-orthovandate (Sigma), 5 mg/mL protease 
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inhibitor cocktail (Sigma). Nuclear and cytoplasmic protein fractions were separated by 
centrifugation (x 1800g). The pellet containing nuclear proteins was re-suspended in 
hypertonic buffer containing 20 mM Hepes (pH 7.9), 400 mM NaCl, 1 mM EDTA, 20% 
Glycerin, 0.1% Triton-X, 0.5 mM DTT (Roche), 1 mM Pefabloc, 1 mM sodium-orthovandate, 
5 mg/mL protease inhibitor cocktail and incubated for 15 min at 4 °C. The lysate was 
subjected to centrifugation (x 16,000g) and the supernatant containing the nuclear proteins 
was collected. Protein quantification was performed using Bradford reagent (Bio-rad, Munich, 
Germany). For Western blot analysis, 20 µg of protein was loaded on an 8% SDS gel, 
separated by electrophoresis and blotted onto nylon membrane. The membrane was exposed 
to anti-STAT-3 primary antibodies and mouse-IgG secondary antibodies conjugated to horse 
radish peroxidase. The enzymatic reaction was visualized using ECL reagents (ECL kit, 
Amersham Biosciences, Freiburg, Germany). 
For electrophoretic mobility shift assays, 5 µg of nuclear protein was incubated with 32P-
labelled synthetic complementary oligonucleotides. SIE-probe 5’-AGCTTCATT 
TCCCGTAAATCCCTA binds to STAT3 and STAT1, OCT1 octamer probe 5’-
GATCCTTAATAATTTGCATACCCTCA was used as a control. Protein-DNA interactions 
were performed in EMSA buffer containing 10 mM HEPES (pH 7.9), 50 mM NaCl, 0.1 mM 
EDTA, 1 mM DTT (Roche), 5% glycerine, 0.1% NP-40 (Sigma), 1 mM Pefabloc, and 5 mM 
sodium-orthovandate. Supershift analysis was performed by preincubating the nuclear 
proteins with a monoclonal antibody recognizing STAT3 or a mouse IgG1 isotype 
monoclonal antibody, respectively. Protein-DNA complexes were resolved on a 5% native 
PAGE using 0.25 x TBE. Autoradiography was performed using a Fujix BAS 1000 (Fuji 
photo film co., LTD, Japan) imaging analyzer. 
 
RNA isolation and Real Time PCR:  Total RNA was isolated with “Absolutely RNA mini 
prep kit” (Stratagene, La Jolla, CA).  cDNA was synthesised by using oligo dT primer and 
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expand reverse transcriptase (Roche). Gfi1 expression was determined by Real Time PCR 
using the specific forward primer 5’-TCCAGTGTGCAAAGCTCATC  and reverse primer 5’-
TCCACAGCTTCACCTCCTCT.  GAPDH specific primers were used as internal controls 
(forward primer 5’ GTCAGTGGTGGACCTGACC; reverse primer 5’-
TGAGCTTGACAAAGTGGTCG). The PCR reaction was performed in duplicates using a 
LightCycler–FastStart DNA Master SYBR Green I kit (Roche) according to the 
manufacturer’s instructions. 
 
Retroviral gene transfer: The murine Gfi1 cDNA was cloned into the retroviral vector SFb-
91-IRES-EGFP, kindly provided by C. Baum, Hannover. Recombinant VSV-G pseudotyped 
retroviruses were generated using transient transfection into the packaging cell line 293GPG 
(Klein et al., 2000). For retroviral gene transfer, Sca-1+lin- progenitor cells were stimulated 
for 48 hours in the presence of a stem cell cytokine cocktail (see above) and transduced at a 
multiplicity of infection (MOI) of 10 in the presence of 8 µg/ml polybrene (Sigma). In brief, 
cells were exposed to recombinant retrovirus for 1 hour at 37 °C, followed by spinoculation 
for 2 hours at x 700 g and further incubation at 37 °C in 5% C02. Subsequently, cells were 
washed, cultured for additional 48 hours in the presence of the stem cell cytokine cocktail and 
used for in vitro and in vivo experiments. The average transduction efficiency was 50-60%. 
 
In vivo studies: To generate hematopoietic chimeras, red blood cell depleted bone marrow 
cells (106) from CD45.2+ Gfi1+/+ or Gfi1-/- mice were  intravenously injected into irradiated (9 
Gy) CD45.1+ recipient mice. For transplantation of retrovirus transduced hematopoietic stem 
cells, 0.5-1 x 105 transduced progenitor cells were transferred into irradiated (4.5 Gy) 
CD45.1+ recipient mice. DC reconstitution was assessed 4-7 weeks after transplantation of 
stem cells. To assess DC maturation in vivo, 4 week old Gfi1-/- and Gfi1+/+ control mice were 
injected i.p. with either LPS (100 ng/g body weight) or a-CD40 monoclonal antibodies (50   
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µg/mouse). 24 hour after injection mice were sacrificed and single cell suspensions were 
prepared from spleen and stained for DC markers and analyzed by flow cytometry. 
 
DNA Microarray Hybridization and Analysis: Quality and integrity of the total RNA 
isolated from 2-10 x 106 FDCP mix cells was controlled by running all samples on an Agilent 
Technologies 2100 Bioanalyzer (Agilent Technologies; Waldbronn, Germany). For biotin-
labelled target synthesis starting from 3 µg of total RNA, reactions were performed using 
standard protocols supplied by the manufacturer (Affymetrix, Santa Clara, CA). Briefly, 5 µg 
total RNA was converted to dsDNA using 100 pmol of a T7T23V primer (Eurogentec; 
Seraing, Belgium) containing a T7 promotor. The cDNA was then used directly in an in vitro 
transcription reaction in the presence of biotinylated nucleotides.  
The concentration of biotin-labelled cRNA was determined by UV absorbance. In all cases, 
12.5 µg of each biotinylated cRNA preparation were fragmented and placed in a hybridization 
cocktail containing four biotinylated hybridization controls (BioB, BioC, BioD, and Cre) as 
recommended by the manufacturer. Samples were hybridized to an identical lot of Affymetrix 
MG-U74Av2  for 16 hours. After hybridization, the GeneChips were washed, stained with 
SA-PE and read using an Affymetrix GeneChip fluidic station and scanner.  
 
Bioinformatics: Gene expression levels were determined by means of Affymetrix's 
Microarray Suite 5.0 (MAS 5.0). MAS 5.0 software algorithms allow quantitative estimation 
of gene expression and a p-value to establish a confidence level concerning the accuracy of 
measurement of an mRNA of interest (detection p-value) and changes in gene expression 
(change p-value). Concerning the measured p-values the criteria of present (P) or absent (A) 
define the quality of signal measurement, and increase (I) or decrease (D) define the signal 
change, respectively. For normalization all array experiments were scaled to a target intensity 
of 150, otherwise using the default values of the Microarray suite. Filtering of the results was 
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done as follows: Genes are considered as regulated  when their fold change is greater than or 
equal 2 or less than or equal –2, the change p-value not "NC" (No Change) and at least one of 
the two compared signals was detected by high accuracy (absent call for both signals were not 
allowed). 
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4. Results 
4.1.1 DC differentiation from well-defined and available hematopoietic progenitor cell 
lines  
The first goal of this thesis was to identify a cell line permissive for DC differentiation in vitro 
in the presence of recombinant cytokines that promote DC differentiation (GM-CSF and IL-
4). In this regard the following cells were tested, 
1. 32D cells  
2. FDCP- mix cells 
In a first series of experiments, 32D cells were incubated in the presence of recombinant 
murine GM-CSF and IL-4 at 50 ng/ml and  analyzed for expression of the cell surface 
markers CD11c, CD40, CD80, CD86, and MHC class II. However, the cells did not 
differentiate into DCs, as assessed by FACS analysis. Even upon permutation of multiple 
experimental variables such as treatment with GM-CSF, TNF-a, LPS (lipopolysaccharide) the 
results were negative (data not shown). 
In contrast, a systematic analysis of in vitro differentiation properties of FDCP-mix cells 
yielded more promising results. Multiple experimental variables were tested to optimise 
differentiation conditions such as such as in the presence of horse serum or fetal calf serum, 
various concentrations of IL-3, GM-CSF and TNF-a, and various exposure periods of cells 
with the mentioned cytokines. The capacity of the differentiation of the FDCP- mix cells into 
dendritic cells was tested by FACS analysis after staining the in vitro differentiated cells with 
dendritic cell specific surface markers (MHC class I and II, CD80, CD86, CD40 and CD11c). 
For optimizing the differentiation condition, FDCP- mix cells were cultured in the presence of 
0.5 %, 1 % and 10 % of WEHI supernatant (source of mIL-3), with and without GM-CSF. 
After culturing the cells for 3-7 days in the presence of GM-CSF (cytokine that influences 
myeloid dendritic cell differentiation), cells were taken for FACS analysis to study the 
expression of surface markers. FACS data indicate that at low concentrations (0.5 % and 1 %) 
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IL-3 favors the differentiation of FDCP- mix cells into dendritic cells (Fig 4.1.1.1) upon GM-
CSF treatment.  
 
 
 
 
 
 
 
 
 
From the above experiment it was inferred that low concentrations IL-3 favors the 
differentiation of FDCP- mix cells into DCs. However previous studies report that FDCP- mix 
cells can survive only in an appropriate concentration of IL-3, as they are basically IL-3 
dependent cells. The definition of an optimal concentration of IL-3 for both survival and 
differentiation was crucial for further differentiation studies. To find the minimal 
concentration of IL-3 necessary for survival, the FDCP- mix cells were cultured in the 
presence of 0.5 %, 1 % and 10 % of WEHI supernatant (as a source of mIL-3). After 3 days of 
culture the cells were stained with propidium iodide to distinguish the viable cells from dead 
cells and taken for FACS analysis. FACS data indicate that survival of FDCP- mix cells is 
proportional to IL-3 concentration. It was observed that in 0.5 % of IL-3 supernatant only 60 
% of the cells were viable, in 1 % IL-3 supernatant 91 % of the cells were viable and in 10 % 
IL-3 supernatant 99 % of the cells were viable (Fig 4.1.1.2). 1 % WEHI supernatant was 
determined as the optimal concentration for the DC differentiation experiments, since 
viability and differentiation were best. 
 
Figure 4.1.1.1. Effect of IL-3 concentration in the 
differentiation of FDCP- mix cells into dendritic 
cells. 
(a) cells were cultured in the presence of 0.5 % of 
WEHI supernatant (source of mIL-3)  with GM-
CSF. (b) Cells cultured in 1 % of WEHI supernatant  
with GM-CSF. (c) Cells cultured  in 10 % WEHI 
supernatant with GM-CSF. Cells were cultured in 
presence of GM-CSF for 3 days. 
Cells were treated with CD80, CD86, CD40, CD11c  
and  MHC class II  monoclonal antibodies and with 
the respective isotype controls. Histograms with 
black line represent the isotype controls and 
histograms with gray line  represent the expression 
of the indicated  surface marker. Fluorescence intensity (in log scale) 
CD80 CD86 CD40 CD11c I-Ab 
(a) 
(b) 
(c) 
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For differentiating FDCP- mix cells into dendritic cells, the cells were cultured in the presence 
of 1% of WEHI supernatant (as a source of IL-3) and recombinant murine GM-CSF 
(100u/mL) for 8 days. Fig 4.1.1.3 indicates the DC specific surface marker expression in 
differentiated FDCP- mix cells. The results of the FACS analysis suggest that FDCP- mix 
cells can be differentiated into dendritic cells. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
These studies suggest that FDCP- mix cells are permissive for DC differentiation in vitro. 
However, the following caveats had to be taken into consideration: 
1- Atypical dendritic cell morphology 
2- Incomplete DC differentiation (persistent contamination of granulocytes and 
macrophages). 
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Figure. 4.1.1.2. Viability of FDCP-mix  cells at 
increasing IL-3 concentrations.  Bar diagram represents 
the percentage of  viable cells in the y axis and the 
corresponding IL-3(WEHI supernatants concentration in 
the X axis.  
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Figure. 4.1.1.3. Differentiation of FDCP-mix cells into DCs.   
Cell surface marker analysis of FDCP-mix cells after differentiation into DCs, open histograms represent 
expression of indicated markers, shaded histograms represent isotype controls. 
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4.1.2.1 Generation of a novel hematopoietic progenitor cell line-CR1-mix 
 
Given the inherent limitations of 32D and FDCP- mix cells, an effort was made to create a 
progenitor cell line that allows an optimised DC differentiation system. Various defined 
transgenes have been used to immortalise HSC (Bunting KD et al., 1999; Just U et a1, 1995; 
Audet j et al 2001; Morrow M et al., 2004; Ye M et al., 2003; Varnum F et al., 2000; 
Antonchuk J et al., 2002; Krosl J et al., 2003; Reya T et al., 2003; Pinto O P et al., 2002). 
We have made use of a retrovirus encoding the transcription factor Notch1. The strategy 
followed for making CR1 was initially described by Pears WS et al (2000). This approach 
utilized the retroviral mediated expression of intra cellular domain region of the transcription 
factor notch1 (ICN) to immortalize hematopoietic stem cells. However the generation of a 
hematopoietic cell line differentiating into DCs has not been reported earlier. The retroviral 
particles for the study were produced by transfecting the packaging cell line 293GPG (Klein 
et al, 2000) with the retroviral transfer vectors (kindly provided by David Scadden, Boston ) 
encoding either intracellular domain of Notch1(ICN) along with IRES EGFP (MSCV-ICN-
GFP) or EGFP (MSCV-GFP) only (Fig 4.1.2.1.). 
 
  
 
 
 
 
 
 
The VSVG pseudotyped viral particles were collected for 5 days and the viral supernatant was 
filtered and concentrated by spinning the soup at (16,000 X g) for three and half hours. The 
viral titer of the concentrated virus was determined by transducing 3T3 fibroblasts cells. Then 
murine HSC(Sca-1+ Lin-) cells from the total bone marrow cells were sorted with moflow cell 
 
   LTR GFP IRES
 
    
LTR 
I
ICN LTR IRES GFP LTR 
Figure. 4.1.2.1. Retroviral constructs. 
cDNAs encoding either GFP(top panel) 
or ICN IRES GFP(bottom panel) were 
cloned into Murine Stem Cell Virus  
backbone plasmids. 
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sorter (DAKO cytomation, Sweden ). The sorted cells were pre-stimulated with a stem cell 
cytokine cocktail (that contains recombinant murine cytokines; IL-3, IL-6 and SCF, and 
recombinant human cytokines; Flt3L and TPO) for 36 hours and transduced with a 
multiplicity of infection (MOI) 10 with retroviruses either encoding ICN-IRES-GFP or GFP 
only. The transduction efficiency was determined on the third day of transduction by 
measuring the GFP positive cells by flow cytometry. The transduction efficiencies were 41% 
and 61% in the cells transduced with either ICN-GFP or GFP respectively (Fig 4.1.2.2.a). To 
check the growth potential and dependency of the ICN transduced cells in the presence of 
different cytokines, cells were cultured in the presence of indicated cytokine combinations. As 
Fig 4.1.2.2.b suggests, only the notch transduced Sca-1+lin- cells could survive (~80%) in the 
presence of the complete cytokine cocktail (mentioned above), where as the viability of the 
GFP-transduced Sca-1+lin-  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cells was almost lost (~10%) on day 30 of culture. Next, the dependency and the viability of 
the ICN transduced Sca-1+lin- cells on individual cytokines of the cytokine cocktail were 
determined. As the Fig 4.1.2.2.b suggests, the viability of the cells that were cultured only in 
Figure. 4.1.2.2 Generattion of a novel IL-3 dependent cell line, CR1-mix cells. 
a. Sca-1+Lin- cells were transduced (MOI 10) with retroviruses encoding either Notch1-IRES-GFP(right) or  
GFP(left) followed by a 36 hour pre-stimulation with stem cell cytokine cocktail. Transduced cells were 
analysed for GFP expression by flowcytometer after  78 hours of  transduction. 
b. The ICN IRES GFP(black bars) and  GFP(white bars) transduced cells were cultured under mentioned 
cytokine combinations to check their  dependence on individual cytokines. Cells were harvested 30 days after 
culture and their viability was calculated after staining the cells with propidium iodide and subsequent 
flowcytometric analysis.  
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the presence of IL-3 or in a combination of IL-3 and SCF was comparable with the viability 
of the cells that were cultured in a complete cytokine cocktail, however viability was almost 
lost in the cells that were cultured in the presence of either IL-6 or SCF alone. 
These data suggest that the transduction of Sca1+lin- cells with ICN immortalises the cells and 
that IL-3 is the most important and crucial cytokine for the viability of the ICN transduced 
Sca-1+lin- cells. This is in line with the available data that most of the hematopoietic 
progenitor cells are IL-3 dependent. To check the proliferation potential of the IL-3 dependent 
cells over a longer time period, the cells were continuously cultured in the presence of IL-3 
(10ng/mL). The cells continued to proliferate for more than 6 months. It was concluded that 
the cells were immortalised and emerged as a cell line which was named as ‘CR1-mix’. 
 
4.1.2.2 Genetic and immunophenotypic characterization of CR1-mix 
In many immortalized cell lines the “immortal” phenotype is associated with karyotypic 
abnormalities that could hamper molecular genetic and cell biological investigations of 
developmental pathways.  
To investigate whether the cell line ‘CR1- mix’ has undergone some detectable chromosome 
changes such as chromosomal translocation or rearrangement, the cells were subjected to 
SKY analysis (in collaboration with Prof. Schlegelberger, Institute of Cellular and Molecular 
Pathology, MHH, Hannover). Spectral karyotyping of 10 metaphases revealed a normal 
diploid chromosome pattern without any evidence of clonal numerical or structural 
aberrations (Fig 4.1.2.3). This finding suggests that the karyotype of CR1- mix cells remains 
stable even 12 months after in vitro propagation. 
It was of paramount importance to investigate whether CR1- mix has undergone spontaneous 
differentiation as a consequence of continuous culture in vitro for more than 12 months. To 
this end, cells were checked for the expression of surface markers of myeloid (CD11b, GR-1, 
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CD11c), erythroid (TER119) and lymphoid (B220, CD3e, NK1.1, CD11c) lineages. As 
inferred from the figure 4.1.2.4, CR1- mix cells were clearly negative for all the lineage 
markers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 4.1.2.3. SKY analysis  of CR1-mix 
cells. 
CR1- mix cells were harvested and their 
metaphase chromosomes were assessed by 
SKY technique for abnormal chromosome 
features and genetic recombinations. 
Figure. 4.1.2.4. Analysis on CR1-mix cells for their 
expression of lineage markers. 
CR1-mix cells were stained with lineage antibodies(open 
histograms) and their respective isotype controls(filled 
histogram). Cells were analysed for the expression of 
lineage antibodies by flow cytometer. 
B220
CD11b
NK1.1
Gr-1 
CD3e 
Ter119
CD11c 
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In addition, to check whether the CR1- mix cells were maintained in a progenitor state, cells 
were analysed for their expression of various hematopoietic stem/ progenitor cell markers 
such as Sca-1, c-kit, Thy1.2, IL-7Ra and Flt3. It was noticed that CR1- mix cells do express 
hematopoietic stem cell markers Sca-1 (73%), c-kit (92%) Thy1.2 (32%), and lymphoid 
progenitor markers IL-7Ra(4%) and Thy1.2 (32%) (Fig 4.1.2.5). Moreover, it was noticed 
that CR1- mix cells also express dendritic and NK cells progenitor marker-Flt3 (10%) in a 
minor proportion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, from the above studies, it was noticed that CR1-mix cells represent a 
heterogeneous cell population that comprises progenitor cells of more than one lineage. 
Especially the expression level of Sca-1, an antigen that is being primarily expressed by all 
the hematopoietic stem and progenitor cells, was quite heterogeneous. Based on this 
observation, it was speculated that this variation in Sca-1 expression could represent a 
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Figure. 4.1.2.5. Immunophenotypic analysis of CR1-mix cells.  
Cells were stained with antibodies that recognise mentioned surface markers and analysed 
by flow cytometer. The gated regions indicate the frequencies of cells expressing the 
respective marker. 
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heterogeneous precursor populations derived from independent clones. In an effort to address 
this hypothesis, CR1-mix cells were stained with Lineage, Sca-1, c-Kit, and either Thy1.2 or 
IL-7Ra antibodies and analysed by flow cytometry.  Lin- CR1-mix cells were gated (G1) and 
the Sca-1, c-kit expression of the gated cells was analysed (Fig 4.1.2.6). Three distinct subsets 
(G2, G3 and G4) were discriminated based on Sca-1/c-kit expression and the expression 
levels of IL7Ra and Thy1.2 in each of these subsets was analysed. Data of these experiments 
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Figure. 4.1.2.6.  Analysis of  CR1-mix cells for their expression of  stem cells/progenitor   cell 
markers. 
Cells were stained with lineage, Sca-1, c-kit, IL 7R-a  and Thy1.2  antibodies and  
analysed by flow cytometer. Lineage negative cells were  gated (G1) and analysed for 
Sca-1 c-kit expression. Sca-1low c-kitlow, Sca-1high c-kithigh  , Sca-1neg c-kithigh cells were 
gated ( G1, G2 and G3 respectively) and their expression levels of  IL7R-a  and Thy1.2  
markers were analysed. 
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identify at least 3 distinct progenitor subsets that can be discriminated as Lin-Sca-1highc-
kitlowIL7Ra+ Thy1.2high, Lin-Sca-1highc-kithighIL7Ra-Thy1.2+ and Lin-Sca-1lowc-kithighIL7Ra-
Thy1.2high in the pool of CR1-mix and thus represent a heterogeneous progenitor cell 
population comprising various maturation stages. Furthermore, the clonality of this cell line is 
currently being investigated by southern blot analysis. 
To check the differentiation potential of CR1-mix in vivo into committed hematopoietic 
lineages, the CR1-mix cells were transplanted into lethally (9.5 Gy) and sub-lethally (4.5Gy) 
irradiated CD45.1 congenic recipient mice. During the first three weeks of transplantation, 
most of the mice from the lethally irradiated group died, presumably due to the inability of 
CR1-mix cells to provide radioprotection. The sublethally irradiated group was sacrificed 
after five weeks of transplantation and the cells of bone marrow, spleen and thymus were 
stained with defined antibodies to recognize the differentiation of CR1-mix into various 
lineages and analyzed by flow cytometry for the presence of donor derived hematopoietic 
cells. Interestingly, CR1-mix derived cells (CD45.2) were found (Fig 4.1.2.7) in bone marrow 
(7-12%), spleen (11-13%), and thymus (32-35%). 
: 
 
 
 
 
 
 
 
The differentiation potential of CR1-mix cells was studied by gating the CD45.2 cells and 
analyzing the surface marker expression. As inferred from the Fig 4.1.2.8,  CR1-mix cells 
could differentiate into T-cells (CD3e), B cells (B220), (NK1.1), DCs (CD11c), macrophages 
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Figure. 4.1.2.7. In vivo proliferation capacity of CR1-mix 
cells. 
CR1-mix cells(1 x106) were transplanted(N=3) i.v. into 
sublethally (4.5Gy) irradiated Ly5.1 recipient mice. Mice 
were analysed on 6(sublethally irradiated) weeks after 
transplantation. Bonamarrow(White bars), Spleen(gray 
bars), and Thymus(black bars) of transplanted mice were 
sacrificed, single cell suspensions were made, stained with  
CD45.2  antibody and analysed by flow cytometer. 
CD45.2 positive cells were gated and their relative 
frequencies were determined.  
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(CD11b, F4/80) and granulocytes (GR-1), however none of the CD45.2 positive cells were 
found to express erythroid markers, suggesting that ICN-transduced cells fail to differentiate 
into the erythroid lineage. 
In summary, CR1-mix cells represent a genomically stable, pluripotent cell line that is 
permissive for DC differentiation in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluorescence intensity
C
el
l c
ou
nt
s
B220
CD11b
CD3e 
Gr-1 
NK1.1
CD11c 
CD45.2 
FS
c
12%
R1
Figure. 4.1.2.8. In vivo differentiation potential of  CR1-mix cells  into defined hematopoietic 
lineages. 
CR1-mix cells (1 x106) were transplanted i.v. into sublethally (4.5Gy) irradiated Ly5.1 recipient 
mice. Mice were analysed 6 weeks after transplantation. Spleens of transplanted mice were 
harvested(n=3), single cell suspensions were made, stained with antibodies recognising either 
defined hematopoietic lineage (open histograms)  or their corresponding isotype control (filled 
histograms) and analysed by flow cytometry.  
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4.1.2.3 Differentiation of CR1-mix cells into dendritic cells 
Next, I determined whether CR1-mix cells could be differentiated in DCs in vitro. As the 
primary aim of making the CR1-mix cell line was to differentiate them into functionally 
mature dendritic cells, these cells were subjected to various differentiation conditions such as 
GM-CSF concentration, presence or absence of IL-3, with and without addition of TNF-a.  
As CR1-mix cells are IL-3 dependent cells, it was reasonable to check whether the 
concentration of IL-3 plays crucial role in DC differentiation. It was noticed that at higher 
concentration of IL-3, CR1-mix cells don’t differentiate into dendritic cells, whereas at 
decreasing concentrations of IL-3, they could clearly differentiate into DCs (data not shown) 
as documented by the expression of DC specific surface markes (CD11c, CD40, CD80, 
CD86, MHC Class II, MHC Class I upregulation).  
In contrast to FDCP-mix cells, CR1-mix cells could efficiently differentiate into DCs in the 
absence of IL-3.  Therefore, in all subsequent experiments the DC differentiation experiments 
CR1- mix cells were cultured in the absence of IL-3. Fig 4.1.2.9.a compares the DC specific 
surface marker expression in undifferentiated CR1-mix (left panels) with CR1-mix derived 
dendritic cells (right panels) after culturing them in the culture medium containing GM-CSF 
in absence of IL3 for 8 days. Fig 4.1.2.9.b compares the morphology of undifferentiated CR1-
mix with CR1-mix derived dendritic cells. Taken together, these results suggest that CR1-mix 
cells could be differentiated into dendritic cells upon exposure to GM-CSF in vitro and thus 
represent an ideal cell line to study molecular changes governing DC differentiation. 
An alternative differentiation pathway into DCs is controlled by the cytokine Flt3L. Flt3L 
induces differentiation of plasmacytoid DCs in vitro. Interestingly, it was noticed that CR1-
mix cells could also efficiently differentiate into plasmacytoid DCs in vitro. More than 95% 
of the DCs generated in the presence of GM-CSF and IL-4 showed morphological and 
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immunophenotypical features of myeloid DCs (expression of the cell surface markers MHC-
II, CD11c, CD40, CD80 and CD86), whereas 70% of DCs selectively grown in the presence  
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Figure. 4.1.2.9. In vitro differentiation 
of CR1-mix cells into DCs. 
a. CR1-mix cells were cultured in the 
presence of GM-CSF for 7 days. On day 
8, cells were harvested and stained with 
DC specific antibodies and analysed flow 
cytometer. Undifferentiated CR1-mix 
cells were used as controls.  
b. Morphological studies of in vitro 
differentiated DCs. CR1-mix derived DCs 
(bottom panels) were visualized under the 
microscope (100x magnification). As 
controls undifferentiated CR1-mix cells 
(top panels) were used. 
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of Flt3L co-expressed CD11c and B220, a phenotype that characterises plasmocytoid DCs 
(Fig 4.1.2.10). 
 
 
 
 
 
 
 
 
To functionally characterise the in vitro generated CR1-mix derived DCs and to compare 
them with the bone marrow derived primary DCs, the ability of CR1-mix derived myeloid 
dendritic cells to stimulate allogenic T cells was assessed. CR1-mix derived DCs and BM 
derived DCs were irradiated (30 Gy) and cultured with allogenic T cells in an increasing ratio 
of stimulators (DCs) to effectors (T cells) for 48 hours. Cells were further incubated for 12 
hours after adding the radio labelled thymidine(3H). The proliferation of T cells was studied 
by measuring the incorporated radioactive thymidine by scintillation counting. Fig 4.1.2.11 
indicates that CR1-mix derived DCs exhibit high stimulatory potential to induce allogenic T 
cell proliferation and the T cell stimulation capacity of both bone marrow derived DCs and 
CR1- mix derived DCs are comparable (data not shown).  
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Figure. 4.1.2.10. In vitro differentiation of 
CR1-mix cells into pDCs. CR1-mix cells were 
cultured in the presence of either GM-CSF (left 
panels) or Flt3L (right panels) for 10 days. Cells 
were harvested on day 11, stained with pDC 
specific antibodies and analysed by flow 
cytometer. 
Figure. 4.1.2.11 Allogenic T cell stimulation 
capacity of CR1- mix derived DCs.  
CR1-mix cells were differentiated in the 
presence of GM-CSF for 7 days. Increasing 
numbers of  irradiated DCs were incubated with 
allogenic lymph node cells (1 x 105) for 48 
hours. Following a 12 hour pulse with 3H 
thymidine, the proliferating T cells were 
measured. Un stimulated CR1-mix cells were 
used as controls. 0 50 
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Furthermore, the ability of CR1-mix derived dendritic cells to secrete IL12p70 upon TNF-a 
exposure was examined. Both CR1-mix derived dendritic cells and BM derived dendritic cells 
were differentiated in vitro and stimulated for 48 hours in the presence of TNF-a. Supernatant 
of the cells was collected and ELISA was performed. As represented in the Fig 4.1.2.12, there 
is a 10-fold induction of IL12p70-secretion by CR1-mix cells upon stimulation with TNF-a, 
moreover the quantity of IL-12p70 was comparable in both primary and CR1-mix-derived 
DCs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Hence it was concluded that constitutive notch 1 expression immortalises hematopoietic cells 
with a DC differentiation potential. Additionally, the thus obtained DCs are morphologically, 
immunophenotypically and functionally comparable with the primary bone marrow derived 
DCs.  
In summary, the present studies yielded both a conventional cell line (FDCP-mix) and a novel 
and optimised cell line (CR1-mix) that were available for the study of GM-CSF dependent 
transcription factor up regulation during DC differentiation in vitro. 
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Figure. 4.1.2.12. IL12 secretion by CR1-mix 
derived DCs. CR1-mix cells were differentiated in the 
presence of GM-CSF for 7 days. On day 8 cells were 
stimulated with TNF-a for 48 hours and the 
supernatant was collected. ELISA was performed to 
quantify the IL12 secretion. The IL12 secretion profile 
of CR1- mix derived DCs was compared with bone 
marrow derived DCs. Unstimulated cells were used as 
controls.  
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4.2.1.1 Microarray analyses to identify transcription factor controlled early DC 
development in FDCP-mix cells. 
To identify the master regulators that control dendritic cell development, microarray analyses 
were performed with the murine hematopoietic progenitor cell line FDCP-mix that is 
permissive for DC differentiation in the presence of GM-CSF. It was reasoned that GM-CSF 
modulates a defined set of decisive transcription factors governing DC differentiation during 
the early stages. To this end, total RNA from FDCP- mix was isolated in duplicates at hours 
0, 6, 24 and 48 of the in-vitro differentiation system after addition of GM-CSF (100 u/ml). 
The extracted RNA was hybridised in duplicates to Affymetrix GeneChips® and analysed by 
K-means cluster analysis. Fig 4.2.1.1 represents cluster analysis of the genes that were 
upregulated during DC differentiation at early time points.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 A certain discrepancy has been noticed between the results of the duplicates at all chosen 
time points except at hour 48. It was believed that this discrepancy could be due to the 
Figure. 4.2.1.1.  Cluster analysis of differentially 
expressed genes. 
 Graphic representation of expression profile analysis 
of selected transcription factors up regulated in  
GM-CSF-treated FDCP-mix cells. Relative expression 
(normalized to the median) is displayed as color 
(green = normalized expression level below, black = 
near to, and red = above the median).  Fold Change 
(hour 48 versus hour 0) is calculated by Affymetrix 
MAS 5.0 and p-values are based on statistical 
parameters as described for MAS 5.0 software. 
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presence of contaminating granulocytes and macrophages in addition to DCs. However, taken 
together at 6 hours 17 genes were upregulated and 10 genes were downregulated, at 24 hours 
57 genes were upregulated and 15 genes were downregulated, and at 48 hours 263 genes were 
upregulated and 116 genes were downregulated. 
The goal of the study was centered the question to identify the transcription  factors controling 
of DC differentiation. Therefore, a special focus was given to transcription factors that were 
upregulated at the given time points. A total of 28 transcription factors, (3 at 6 hours, 7 at 24 
hours and 18 at 48 hours) were found to be upregulated (table 4.2.1.1) from the total list of 
337 upregulated genes at all time points. 
Table 4.2.1.1. List of   transcription factors upregulated at chosen time points during  
DC differentiation 
 
No Name of the transcription factors 
 
Fold change Time points 
1  Histone deacetylase 1 2.4 6 hrs 
2  Hox 2.4 1.84 6 hrs 
3  Zinc ring finger protein 1 2.72 6 hrs 
4  Activating transcription factor 4 1.59 24hrs 
5  Zinc finger protein, subfamily 1A, 1 (Ikaros) 2.5 24hrs 
6  Leukemia/lymphoma related factor 7.38 24hrs 
7  General transcription factor II I 2.02 24hrs 
8  Pre B-cell leukemia transcription factor 3 7.8 24hrs 
9  Homeo box, msh-like 1 3.36 24hrs 
10  GA repeat binding protein, alpha 6.81 24hrs 
11  Inhibitor of DNA binding 1 2.66 48 hrs 
12  Breakpoint cluster region protein 1 1.77 48hrs 
13  Recombination activating gene 2 10.8 48hrs 
14  CCAAT/enhancer binding protein (C/EBP), delta 2.9 48hrs 
15  Histone 4 protein 2.09 48hrs 
16  POU domain, class 2, associating factor 1 3.22 48hrs 
17  Friend leukemia integration 1 1.89 48hrs 
18  Mini chromosome maintenance deficient 5 (S. cerevisiae) 1.54 48hrs 
19  B-cell leukemia/lymphoma 2 related protein A1b(BCl2 A1b) 12.1 48hrs 
20  Growth factor independent 1 2.21 48hrs 
21  RNA binding motif protein, X chromosome retrogene 1.65 48hrs 
22  Mini chromosome maintenance deficient (S.cerevisiae) 1.57 48hrs 
23  Gene rich cluster, C2f gene 1.61 48hrs 
24  RNA and export factor binding protein 1 1.55 48hrs 
25  CCAAT/enhancer binding protein (C/EBP), delta 2.31 48hrs 
26  Splicing factor 3a, subunit 2, 66kD 1.55 48hrs 
27  CCAAT/enhancer binding protein (C/EBP), beta 1.83 48hrs 
28  Cold shock domain protein A 1.81 48hrs 
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4.2.1.2 Real Time PCR analysis to confirm the expression status of the transcription 
factors in FDCP-mix cells.  
In order to validate the microarray result and to confirm the expression status of the identified 
transcription factors, real time PCR analysis was carried out for all 28-transcription factors 
upregulated as by microarray analysis. In contrast to the microarray data, the real time PCR 
data showed an up regulation of only 6 transcription factors (Fig 4.2.1.2) out of 28 chosen 
candidates, namely Histone Deacetylase1 (6hours), General transcription factor II I (24 hrs), 
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Figure. 4.2.1.2. Real time PCR analysis on candidate transcription factors upregulated during  FDCPmix  
derived DC development. 
FDCP cells were differentiated in vitro into DCs in the presence of GM-CSF and IL-4. During 
early time points of differentiation, cells were harvested and RNA was extracted. cDNA synthesis 
was followed by a semi quantification of the target transcripts using light cycler Real Time PCR 
approach. The  expression status of the transcription  factors in cells that were cultured in the 
presence of  GM-CSF(black bars) was compared with those that were cultured in the absence of 
GM-CSF(white bars).  
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Deacetylase1 (6hours), General transcription factor II I (24 hrs), GAAT enhancer binding 
protein –a(24 hrs), Inhibitor of DNA binding 1(48hrs), Growth factor independent 1(48hrs), 
CAAT Enhancer Binding Protein d(48 hrs). 
 
4.2.2.1 Microarray analyses to identify transcription factor controlled early DC 
development of CR1-mix cells. 
Due to the inconsistency of the microarray results obtained from the duplicate samples of 
FDCP- mix cells, the microarray analysis was repeated using the newly generated cell line 
CR1-mix. As mentioned above, RNA was extracted from CR1-mix cells during early stages 
of DC differentiation (6 hours, 24 hours and 48 hours after addition of GM-CSF). The 
extracted RNA was hybridized to Affymetrix Gene Chips and analyzed by K-means cluster 
analysis. In summary, 628 genes were up regulated at 6, 24, and 48 hours respectively. Out of 
58 transcription factors identified 9 were up regulated at 6 hours (Table 4.2.1.2), 20 were up 
regulated at 24 hours(Table 4.2.1.3)  and 29 were up regulated at 48 hours (Table 4.2.1.4). 
 
      Table 4.2.1.2. List of   transcription factor upregulated after 6 hours of GM-CSF stimulation in  
        CR1-mix cells   
 
 
 
 
 
 
 
 
 
 
No 
 
Name of the transcription factor 
  
Gene symbol 
1 RNA binding motif protein 6 Rbm6 
2 Special AT-rich sequence binding protein 1 Satb1 
3 SRY-box containing gene 4 Sox4 
4 Transcriptional regulator, SIN3B (yeast) Sin3b 
5 RIKEN cDNA 2210412K09 gene 2210412K09Rik 
6 Kruppel-like factor 7 (ubiquitous) Klf7 
7 homeo box A9 Hoxa9 
8 Signal transducer and activator of transcription 5B Stat5b 
9 Hypothetical protein MGC18736 MGC18736 
 57 
Table 4.2.1.3. List of   transcription factor upregulated  after 24 hours of GM-CSF stimulation in  
CR1-mix cells   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2.1.4. List of   transcription factor upregulated  after 48 hours of GM-CSF stimulation in  
CR1-mix cells   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No 
  
Name of the transcription factor 
  
Gene symbol 
1 Ngfi-A binding protein 2 Nab2 
2 Early growth response 1 Egr1 
3 Interferon regulatory factor 7 Irf7 
4 Pleiomorphic adenoma gene-like 2 Plagl2 
5 Tripartite motif protein 30 Trim30 
6 H2.0-like homeo box gene Hlx 
7 Promyelocytic leukemia Pml 
8 Signal transducer and activator of transcription 1 Stat1 
9 Zinc finger protein 36, C3H type-like 1 Zfp36l1 
10 DNA segment, Chr 16, ERATO Doi 465 D16Ertd465e 
11 Avian reticuloendotheliosis viral (v-rel) oncogene related B Relb 
12 Retinoblastoma-like 2 Rbl2 
13 Nucleobindin 2 Nucb2 
14 Transcription factor EC Tcfec 
15 Amyloid beta (A4) precursor-like protein 2 Aplp2 
16 EST AI256856 AI256856 
17 DNA (cytosine-5-)-methyltransferase 3-like Dnmt3l 
18 Early growth response 2 Egr2 
19 Ngfi-A binding protein 2 Nab2 
20 LIM only 4 Lmo4 
 
No 
  
Name of the transcription factor 
  
Gene symbol 
1 Juxn-B oncogene Junb 
2 DNA segment, Chr 16, ERATO Doi 465, expressed D16Ertd465e 
3 Nuclear receptor subfamily 4, group A, member 1 Nr4a1 
4 Nuclear, factor, erythroid derived 2, like 2 Nfe2l2 
5 Interferon concensus sequence binding protein Icsbp 
6 Early growth response 1 Egr1 
7 Interferon regulatory factor 7 Irf7 
8 Jun oncogene Jun 
9 Avian reticuloendotheliosis viral (v-rel) oncogene related B Relb 
10 SFFV proviral integration 1 Sfpi1 
11 H2.0-like homeo box gene Hlx 
12 Transcription factor EC Tcfec 
13 Ngfi-A binding protein 2 Nab2 
14 Tripartite motif protein 30 Trim30 
15 Notch gene homolog 1, (Drosophila) Notch1 
16 CCAAT/enhancer binding protein (C/EBP), beta Cebpb 
17 cAMP responsive element binding protein 3 Creb3 
18 B-cell leukemia/lymphoma 6 Bcl6 
19 DNA methyltransferase 3A Dnmt3a 
20 DNA segment, Chr 16, ERATO Doi 465, expressed D16Ertd465e 
21 E26 avian leukemia oncogene 2, 3' domain Ets2 
22 Interferon activated gene 204 Ifi204 
23 Forkhead box J2 Foxj2 
24 AT motif binding factor 1 Atbf1 
25 Nuclear factor of activated T-cells, cytoplasmic 1 Nfatc1 
26 Early growth response 2 Egr2 
27 Nuclear factor of activated T-cells 5 Nfat5 
28 Zinc finger protein 36, C3H type-like 1 Zfp36l1 
29 Transcriptional regulator, SIN3B (yeast) Sin3b 
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4.2.2.2 Real Time PCR analysis to confirm the expression of the candidate transcription 
factors identified in CR1-mix  
Real Time PCR studies were done in order to reconfirm the expression status of the 
transcription factors that were identified from the global screening using microarrays.  An 
initial screen for transcription factors from the up regulated genes has listed a total of 58 
transcription factors.  
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Figure. 4.2.1.3:  Real time PCR analysis on candidate transcription factors upregulated during  
CR1-mix  derived DC development. 
CR1-mix cells were differentiated in vitro into DCs in the presence of GM-CSF. During 
early time points of differentiation cells were harvested and RNA was extracted. cDNA 
synthesis was followed by a semi quantification of the target transcripts using light cycler 
Real Time PCR approach. Black bars represent the expression of the respective 
transcription factors in the absence of GM-CSF, while the gray bars represent the 
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Figure. 4.2.1.3:  Real time PCR analysis on candidate transcription factors upregulated during  
CR1- mix  derived DC development. 
CR1- mix cells were differentiated in vitro into DCs in the presence of GM-CSF. During 
early time points of differentiation cells were harvested and RNA was extracted. cDNA 
synthesis was followed by a semi quantification of the target transcripts using light cycler 
real time PCR approach. Black bars represent the expression of the respective transcription 
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An initial pre-screening was done based on the signal intensity to choose only those genes that 
have a high probability of upregulation. A total of 35 transcription factors with good signal 
intensities (with signal filters denoted by letter A) were chosen for the Real Time PCR 
studies. The results of the Real Time PCR  (Fig 4.2.1.3) confirmed the upregulation of 27-
transcription factor at mentioned time points. 
Hence, the undertaken transcriptional profiling studies in FDCP mix cell line  have identified 
the involvement of 6 transcription factors. The analysis of CR1-mix cells yielded  27 
transcription factors during the early time points of  DC differentiation.  
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Figure. 4.2.1.3:  Real time PCR analysis on candidate transcription factors upregulated during  
CR1- mix  derived DC development. 
CR1- mix cells were differentiated in vitro into DCs in the presence of GM-CSF. During 
early time points of differentiation cells were harvested and RNA was extracted. cDNA 
synthesis was followed by a semi quantification of the target transcripts using light cycler 
real time PCR approach. Black bars represent the expression of the respective transcription 
factors in the absence of GM-CSF, while the gray bars represent the expression in the 
presence of GM-CSF  
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4. 3. 1. Transcriptional activity of the Gfi1 locus in precursor and mature DC 
For further studies, I chose to focus on a single transcription factor and assess its role in great 
detail. The transcriptional repressor Gfi1 was an interesting candidate, since its role in DC 
development has not been reported. Gfi1 knockout mice  could be obtained from Prof. Tarik 
Möröy, University Hospital Essen. In addition to the Gfi1 knockout mice, a novel Gfi1GFP/- 
knockin mouse has been generated by this laboratory.  
The GM-CSF-dependent Gfi1 upregulation was further confirmed by RT-PCR in CR1-mix 
and primary Sca1+lin- hematopoietic progenitor cells (Fig.4.3.1.1). 
 
 
 
 
 
 
 To assess the physiological expression pattern of Gfi1 in DC, the transgenic Gfi1: GFP 
knock-in mutant mouse system was used. The GFP expression profile in DC development in 
vitro over time was analyzed. Lineage-depleted hematopoietic progenitor cells from Gfi1 +/+ , 
Gfi1 GFP/+ and Gfi1 GFP/GFP mice were purified and the cells were incubated in the presence of 
either recombinant murine GM-CSF or recombinant human Flt3L, two cytokines controlling 
DC differentiation. Aliquots of cells were analyzed for GFP expression by flow cytometry 
every 6-12 hours. 
Expression of GFP revealed transcriptional activation of the Gfi1 locus during early phases of 
DC development and a decline at later phases (Fig. 4.3.1.2.a). However, only in the case of 
GM-CSF a marked increase in the fluorescence intensity during hours 48-72 was observed. In 
homozygous Gfi1GFP/GFP progenitor cells, the levels of fluorescence intensity were generally 
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Figure 4.3.1.1. Quantification of Gfi1 expression in 
CR1-mix and Sca1+in- cells. 
CR1-mix and Sca-1+lin- hematopoietic progenitor 
cells at hour 0(white bars) and 48 hours(black bars) 
after GM-CSF treatment. Shown are the mean 
values of duplicate samples. Data are representative 
of 2 independent experiments. 
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higher and followed a defined pattern over time (Fig. 4.3.1.2.b). This finding might reflect 
Gfi1 autoinhibition in DC development (Raif. et al., 2004), in analogy to a documented role of 
Gfi1 autoinhibition in T cell development. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
To investigate the expression pattern of Gfi1 in differentiated DCs in vivo, the fluorescence 
intensity of various CD11c+ DC subpopulations in lymphoid organs was determined by 
comparing Gfi1GFP/+ and Gfi1+/+ mice. GFP expression was detected at various intensities in 
various subpopulations (CD4+, CD8+, CD4-CD8-, CD11b+, B220+) of CD11c+ DCs obtained 
from spleen, thymus and lymph nodes   (Fig. 4.3.1.3). It was hypothesized that heterogeneity 
in GFP expression in vivo might depend on the activation status of DCs.  
To address this question, the Gfi1GFP/+ mice were injected with LPS or stimulating anti-CD40 
monoclonal antibodies in the peritoneum and the mice were sacrificed 24 hours later. Single 
cell suspensions were made from spleens and lymph nodes. Compared to Gfi1GFP/+ DCs 
isolated from mice treated with PBS, GFP-expression was enhanced in Gfi1GFP/+ DCs 
obtained from mice treated with LPS or anti-CD40 monoclonal antibodies (Fig. 4.3.1.4-top 
panels). Furthermore the expression of Gfi1 in DCs upon activation in vitro was assessed by 
isolating splenic CD11c+ cells by MACS and cultured in vitro for 24 hours after the addition 
of specific stimuli LPS and aCD40 monoclonal antibodies. 
Figure4.3.1.2. Gfi1 expression in DC development in vitro. 
 Lineage-marker depleted bone marrow cells from Gfi1+/GFP mice (a) and Gfi1GFP/GFP mice (b) were cultured 
either in the presence of GM-CSF and IL-4 or Flt3L, respectively. Cells were harvested every 6-12 hours and 
their fluorescence was determined by FACS analysis. Shown is the specific geometric mean fluorescence 
intensity index calculated as follows: GMFIi = GMFI(Gfi1+/GFP) – GMFI(Gfi1+/+). Results represent the average 
values of duplicate samples. Data are representative of 3 independent experiments. 
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Cells were harvested and GFP expression was measured by flowcytometry. Gfi1GFP/+ DCs 
cultured in the absence of an external stimulus was taken for the baseline Gfi1 expression. 
Compared to unstimulated DCs, GFP-expression was enhanced in DCs cultured in the 
presence of either LPS or anti-CD40 monoclonal antibodies (Fig. 4.3.1.4-bottom panels).  The 
data of these experiments suggest that Gfi1 expression is physiologically increased upon DC 
activation in vivo.  
To validate these in vitro and in vivo findings, GFP expression in DC progenitor cells in 
Gfi1GFP/+ mice in vivo was assessed. GFP expression was noticed in both progenitor DCs 
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CD4+ CD8+ CD4- CD8- CD11b+ B220+ 
Figure4.3.1.3. Gfi1 expression in  various DC compartments in vivo.  
Single cell suspensions from spleen(top panels), thymus(middle panels) and lymphnodes(bottom panels)  of  
Gfi1+/GFP mice were stained  with  antibodies recognising different DC subsets and analysed by flow 
cytometer. Distinct  DC compartments were  gated   and analyzed for GFP expression (open histogram). 
Shaded histograms represent the autofluorescence of Gfi1+/+ DCs used as controls. In each experiment, organs 
from 3-5 mice were pooled. Data are representative of 3 independent experiments. 
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Figure 4.3.1.4. Enhanced transcriptional 
activity upon DC stimulation in vivo.
Gfi1+/GFP mice were i.p. injected with LPS 
or anti-CD40 monoclonal antibodies and 
DC fluorescence was measured by flow 
cytometry 24 hours later (open 
histograms). Shaded histograms represent 
the DC fluorescence from PBS-treated 
Gfi1+/GFP mice. 
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 Figure4.3.1.5. Gfi1 expression in  various DC compartments in vivo. Gfi1 expression in precursor 
DCs. Pooled bone marrow cells from 3-5 mice were analyzed for GFP expression in  Lin-c-kit+Flt3+
cells (top panelss)of bone marrow  and CD11c+I-Ab-/ CD11c+I-Ab+ cells of  bone marrow (middle 
panels) and peripheral blood (bottom panels). Open histograms represents GFP fluorescence in 
Gfi1+/GFP cells, shaded histogram represents autofluorescence of Gfi1+/+ cells. Data are representative 
of 3 independent experiments. 
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(CD11c+MHC-ClassII-) as well as differentiated DCs (CD11c+MHC-ClassII+) of bonemarrow 
(Fig. 4.3.1.5-middle panels) and peripheral blood (Fig. 4.3.1.5-bottom panels). 
GFP expression was also noticed in Flt3+c-kit+lin- precursor DCs in the bone marrrow (Fig. 
4.3.1.5-top panels). Data of the above mentioned experiments strongly suggest that Gfi1 
expression is physiologically regulated in both DC progenitors and completely differentiated 
dendritic cells. 
4. 3. 2 Gfi1-/- mice show decreased numbers of DCs in lymphoid organs 
It was reasoned that the distinct expression profile of Gfi1 at early stages of DC development 
might have important implications for the control of normal DC differentiation. To investigate 
the importance of Gfi1 in dendritic cell development, the lymphoid organs of Gfi1-/- and 
Gfi1+/+ mice were assessed for the presence of dendritic cells. In Gfi1-/- mice, the absolute 
numbers of CD11c+ DCs were significantly reduced in lymph nodes (~10fold), spleen 
(~2fold) and thymus (~20fold) (Fig.  4.3.2.1).  
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 Figure 4.3.2.1.   Absolute DC numbers in lymphoid organs of Gfi1-/- mice.  
Gfi1-/- mice and Gfi1+/+ mice (n=3) were sacrificed and single cell suspensions of spleens (upper left), thymi 
(upper right), peripheral lymph nodes (Lower left) and mesenteric lymphnodes (lower right) were pooled 
prior to enumeration. The absolute number was determined based on the relative FACS profile and total 
number of cells. Shown is the average of 3 mice. 
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 Figure 4.3.2.2 Global decrease of DCs  in lymphoid 
organs of  Gfi1-/- mice.  
(a). Dot plots indicating relative decrease of 
CD11c+CD4+ DCs (upper left) and relative decrease of 
CD11c+CD8+ DCs (upper right)  in speen(top panels), 
thymus(middle panels) and  lymph nodes (lower 
panelss). 
(b) Contour plots indicating relative decrease  of 
selective DC subtypes, CD4+ in spleen (top panels), 
CD4+ (middle panels) and CD8high in lymph nodes 
(lower panels). Analysis was done by gating on the total 
CD11c+ cells of the respective organs.  
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In view of the GM-CSF-specific upregulation of Gfi1 during early DC development, it was 
interesting to find out whether Gfi1 may act as a lineage-specific transcription factor in 
“myeloid” versus “lymphoid” DC development. Therefore the analysis was repeated with a 
specific focus on defined DC subpopulations. As shown in  Figures 4. 3. 2.2, 4.3.2.3 and 
4.3.2.4, the relative proportion of all defined DC subtypes, including myeloid, lymphoid and 
plasmocytoid that are described as CD4+, CD8+, CD8-, CD8high, CD4-CD8-, CD11b+ 
CD4+CD11b+, CD4-CD11b+, CD4+CD11b-, B220+ were drastically reduced in the spleen (top 
panels), thymus (middle panels), lymph nodes (bottom panels) of Gfi1-/- mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 4.3.2.3. Global decrease of DCs  in lymphoid organs of  Gfi1-/- mice.  
Dot plots indicating relative decrease of conventional (CD11c+CD11b+) myeloid DCs (upper left) and relative 
decrease of plasmocytoid CD11c+BB220+ DCs (upper right)  in speen(top panels), thymus(middle panels) and  
lymph nodes (lower panels). 
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In the Gfi1-/- mice, relative DC deficiency affected mostly the CD4+ DC compartment in the 
spleen (21% versus 40%, Fig 4. 3. 2.2. top panels), and thymus (10% versus 22%, Fig 4. 3. 
2.2. middle panels), whereas in the peripheral lymph nodes, mostly CD8high expressing cells 
appeared reduced (7% in Gfi1-/- versus 21% in Gfi1+/+, Fig 4.3. 2.2 bottom panels).  
 
 
 
 
 
 
 
 
 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Despite the variations in the relative composition of the DC compartment, the absolute 
numbers of all DC subpopulations were significantly reduced in spleen (Fig 4.3.2.5. top 
panel), thymus (Fig 4.3.2.5. middle panel) and lymph nodes (Fig 4. 3. 2.5. bottom panel).  
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Figure 4.3.2.4. Global decrease of DCs  in lymphoid organs of  Gfi1-/- mice.  
Contour plots indicating  the  relative profile of more specific compartments based on CD4/CD11b 
expression(Upper left) and CD8/CD11b expression (upper right)  in speen (top panels), thymus(middle 
panels) and  lymph nodes (bottom panels). Analysis was done after gating on the total CD11c+ cells of the 
respective organs. 
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This finding was further supported by immunofluorescence studies. Tissue sections of the 
lymphoid organs were stained with monoclonal antibodies that recognize T cells (Thy1.2), B 
cells (B220) and DCs (CD11c). Figure 4.3.2.6 depicts the reduction of dendritic cells in the 
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Figure 4.3.2.5 Reduced  absolute numbers of DC subtypes in  lymphoid organs of Gfi1-/-mice.  
Gfi1-/- mice and Gfi1+/+ mice (n=5) were sacrificed and single cell suspensions of spleens (upper panels), thymi 
(middle panels)  and peripheral lymph nodes (lower panels)  were pooled prior to enumeration. The absolute 
number was determined based on the relative FACS profile and total number of cells. Shown is the average of 
2 independent experiments.  
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Figure 4.3.2.6.   Immunofluorescence studies in  lymphoid organs of Gfi1-/-mice.  
Gfi1-/- mice and Gfi1+/+ mice were sacrificed and spleens (upper panels), thymi (middle panels)  and peripheral 
lymph nodes (lower panels)  were isolated. Cryosections were prepared, fixed and stained with B220-FITC, 
Thy1.2-CyC3, CD11c-APC monoclonal antibodes. Sections were mounted and visualised under the fluorescence 
microscope. 
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 spleen (Figure 4.3.2.6-top panel), thymus (Figure 4.3.2.6-middle panel) and lymph nodes 
(Figure 4.3.2.6-bottom panel) of Gfi1-/- mice. In striking contrast to DCs in lymphoid organs, 
the number of epidermal Langerhans cells was increased (LCs, 92/mm2 in Gfi1-/- versus 
40/mm2 in Gfi1+/+, Fig 4.3.2.7), suggesting that Gfi1 does not play a critical role in the 
differentiation of LCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
To assess whether the decreased number of DCs was due to cell-autonomous or rather 
extrinsic effects, hematopoietic chimeras were generated by transplanting lineage-depleted 
hematopoietic progenitor cells obtained from Gfi1-/- and Gfi1+/+ (CD45.2) into irradiated 
congenic recipient mice (CD45.1). In these chimeras, DCs of donor origin developed only 
from Gfi1+/+ but not from Gfi1-/- progenitor cells (Fig 4.3.2.8.), suggesting that the non-
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Figure 4.3.2.7 Quantification of epidermal 
Langerhans cells.  
Epidermal sheets from Gfi1-/- and Gfi1+/+ mice 
were stained with an APC-conjugated 
monoclonal antibody reacting against I-Ab. 
Characteristic Langerhans cells were visualized in 
a fluorescence microscope (upper panels) and 
their density was determined using calibrated 
grids (lower panel).  
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hematopoietic environment did not contribute any critical factors causing deficient DC 
development in Gfi1-/- mice.  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. 3. 3. Gfi1 controls DC differentiation from hematopoietic stem cells on multiple levels 
In principle, decreased DC numbers in Gfi1-/- mice could be explained by increased turnover, 
aberrant distribution or decreased production of DCs. To assess whether the lack of DCs in 
the Gfi1-/- mice was due to decreased production, distinct progenitor populations were 
analysed. Hematopoietic stem cells (HSC), classically characterized as negative for lineage 
markers and positive for c-kit, Sca-1 and Thy1.2 (Lin- Sca-1+ c-kit+ Thy1.2low) were 
reduced by three fold in Gfi1-/- mice (Fig. 4.3.3.1.a). HSCs give rise to committed progenitors, 
named CMP (lin-IL7R-c-kit+-FcRg+CD34+) and CLP (lin-IL7R+c-kit+). Both CMP and CLP 
contain Flt3+ cells that might represent progenitor cells preceding a DC precursor cell. The 
percentage of CMP cells was decreased, while more committed granulocyte-monocyte 
progenitors (GMPs) were enhanced (36% versus 18%, Fig. 4.3.3.1.b). Similarly the 
percentage of  CLP cells was significantly reduced in the bone marrow of Gfi1-/- mice (0.03% 
in Gfi1-/- versus 1% Gfi1+/+, Fig. 4.3.3.1.c). Furthermore, DC precursor cells in bone marrow 
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Figure4.3.2.8.  Development of DC chimerism upon bone marrow transplantation.  
Lineage depleted bone marrow cells from Gfi1-/- mice and Gfi1+/+ mice (CD45.2) were transplanted into lethally 
irradiated congenic recipient mice (CD45.1). Flow cytometric analysis of splenic DCs reveals donor origin 
(CD45.2, upper left) in Gfi1+/+ transplanted mice and recipient origin (CD45.1, upper right) in Gfi1-/- transplanted 
mice. Data are representative of 2 independent experiments. 
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and peripheral blood, defined as CD11c+ MHC class II- cells (0.3% in Gfi1-/- and 1% in 
Gfi1+/+(Fig. 4.3.3.2.a) and c-kit+Flt+lin- (5% versus 18% of lin- c-kit+ cells, Fig. 4.3.3.2.b), 
were significantly reduced in numbers. 
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Figure. 4.3.3.1.  Hematopoietic progenitor cell analysis in Gfi1-/- mice.  
(a) Contour plot showing decreased hematopoietic stem cells  (G2) in Gfi1-/- mice. Mononuclear bone marrow cells 
were stained with lineage-specific monoclonal antibodies reacting against B220, Gr-1, CD11b, CD4, CD8, Ter119, 
IL-7Ra, and stem cell markers c-kit, Sca-1 and Thy1.2. Lineage negative(G1) cells that are positive for both Sca-1 
and c-kit (G2) were analysed for Th1.2 expression. (b) Contour plots showing  fluorescence profile of Lineage 
negative(G1) bone marrow cells stained  with  Sca-1 and c-kit(top panels). c-kit+/Sca-1- cells (G3) cells were 
analysed for FcRg and CD34 (bottom panels). The frequencies of  of FcR-glowCD34+ common myeloid progenitors 
(G4) and FcR-g+CD34+ granulocyte monocyte progenitors (G5) were calculated, both gated on G3. (c) Contour 
plot showing decreased common lymphoid precursor cells (G5) in Gfi1-/- mice. Mononuclear bone marrow cells 
were stained with FITC-labelled lineage-specific monoclonal antibodies reacting against B220, Gr-1, CD11b, 
CD4, CD8, Ter119; IL-7Ra is visualized upon staining with Streptavidin PerCP. 
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Although the exact lineage relations of CMP, CLP, pre-DCs and differentiated DCs are 
currently not yet known, these data suggest that Gfi1 plays a critical role in shaping lymphoid 
and myeloid hematopoiesis. In particular, a severe reduction in lymphoid and DC progenitors 
is contrasted by a relative increase of committed granulocyte-monocyte progenitor cells. 
Results from the extensive progenitor analysis suggest that the decreased numbers of DCs in 
Gfi1-/- mice is primarily due to insufficient production.  
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Figure4.3.3.2 Dendritic cell  progenitor analysis in Gfi1-/- mice. 
 (a) Contour plot showing decreased dendritic cell progenitors (CD11c+ IAb-) cells  in peripheral blood (top panels) 
and bone marrow (bottom panels) of  Gfi1-/- mice. (b) Contour plot showing distribution of (Lin-c-kit+B220-Flt3+) 
precursor DC cells. Lin-c-kit positive  cells (top panels) were gated (G6)  and the frequency of  Flt3+B220-cells was 
determined (lower panels). 
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4. 3. 4. Gfi1-/- DCs show functional abnormalities revealing distinct effects in maturation 
and activation profiles 
DC development is not completely abrogated in Gfi1-/- mice. Since Gfi1 is up regulated upon 
DC activation in Gfi1GFP/+ mice, it was interesting to assess whether the remaining DCs in 
Gfi1-/- mice were characterized by functional defects. First, the expression levels of MHC and 
co stimulatory molecules on DCs as markers of the maturation status in lymphoid organs were 
assessed. In contrast to normal expression levels of MHC class I, CD40, CD80 and CD86, a 
significant reduction in MHC class II expression in all DC subtypes in Gfi1-/- mice (Fig. 4.3. 
4.1) was found.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure4.3.4.1. Decreased MHC class II expression in Gfi1-/- DCs.  
(a) MHC class II expression in CD11c+ cells of  spleen (top panels) and lymph nodes (bottom panels). MHC 
Class II expression in  DCs of Gfi1+/+(filled histogram)  and Gfi1-/-(open histogram) mice is compared. 
 (b) Geomean fluorescence index (GMFI) of MHC Class II expression in various subtypes of DCs in spleen 
(upper panels) and lymph node (lower panels) of Gfi1+/+ (open bars)  and Gfi1-/- (filled bars) mice was 
represented. Shown is the average GMFI of two independent experiments, pooling organs from 5 mice. Data are 
representative of 6 independent experiments. 
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To further assess whether DC maturation could be triggered by a response to microbial 
components or inflammatory cytokines, Gfi1-/- and Gfi1+/+ mice were injected with anti-CD40 
monoclonal antibodies or LPS, respectively. 24 hours later, splenic DCs were harvested,  
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Figure 4.3.4.2 Gfi1-/- DCs are refractory to upregulate costimulatory molecules upon stimulation. 
Histograms indicating that Gfi1-/- DCs are refractory to upregulate costimulatory molecules. Gfi1-/- and Gfi1+/+ mice 
were injected with LPS or anti-CD40 monoclonal antibodies. Pooled DCs from 3-5 mice were analyzed for 
expression of CD40, CD80 and CD86, I-Ab(open histograms). Shaded histograms represent expression levels on DCs 
from PBS injected mice used as negative controls.  
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stained, and analyzed by flow cytometry. As shown in Fig. 4.3.4.2, Gfi1-/- DCs were 
refractory to up regulation of the costimulatory molecules CD40, CD80, and CD86. Similar 
findings were noted in bone marrow derived DCs. 
To test whether a decreased level of DC maturation/activation might be associated with 
decreased production of inflammatory cytokines such as IL12, splenic DCs from Gfi1-/- and 
Gfi1+/+ mice were purified and stimulated with TNFa or the Toll-like-receptors ligands LPS 
(TLR2, 4) and CpG (TLR9), respectively. Surprisingly, it was found that Gfi1-/- DCs showed  
 
 
 
 
 
 
 
 
 
 
a higher baseline level of IL12 secretion that could not be further increased upon stimulation; 
suggesting that maturation (expression of MHC class II and costimulatory molecules) and 
activation (expression of IL12) of DCs represent the result of at least partially independent 
and distinct molecular events (Fig. 4.3.4.3).  
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Figure4.3.4.4. Deficient antigen presentation in Gfi1-/- DCs in-vitro. Splenic DCs from Gfi1-/- and Gfi1+/+ mice 
were loaded with peptides and used as antigen presenting cells to stimulate the proliferation of transgenic OT-I 
(upper left) and OT-II cells (upper right), respectively. T-cell proliferation was measured in triplicates by 
incorporation of 3H-Thymidine. Data are representative of 3 independent experiments. 
Figure4.3.4.3. Constitutive secretion of IL12 in 
Gfi1-/- DCs. Splenic DCs from Gfi1-/- and Gfi1+/+ mice 
were purified and stimulated with TNFa and the TLR 
ligands CpG and LPS in duplicates. Shown is one 
representative experiments out of five. Error bars 
represent standard error in ELISA. 
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To further characterize the function of Gfi1-/- DCs, the capacity of Gfi1-/- DCs to present 
specific antigens to T-cells was studied. Splenic DCs from Gfi1-/- and Gfi1+/+ mice were 
isolated and loaded with Ova peptides SIINFEKL and Ova323-339, two epitopes presented by 
MHC class II  and I, respectively. 
The antigen pulsed DCs were incubated with transgenic OT-I and OT-II T-cells recognizing 
Ova peptides in association with MHC class I and class II.  As shown in Figure. 4. 3. 4.4,  
Gfi1-/- DCs induced a significantly reduced OT-I (Fig. 4. 3. 4.4-upper left) and OT-II (Fig. 4. 
3. 4.4-upper right) T-cell proliferation in vitro.  In addition the capacity of Gfi1-/- dendritic 
cells to present a surrogate tumor antigen, ova-albumin,  to ovaspecific T cells (OT-II) was 
analysed. Fig. 4.3.4.5 showst that the Gfi1 deficient DCs had defect in  presenting the ova 
protein to OT-II cells . 
 
 
 
 
 
 
 
 
 
 
 Taken together these data suggest that impaired antigen presentation is an intrinsic feature of 
Gfi1-/- DCs that can not be readily explained by decreased MHC class II expression levels. 
 
4. 3. 5. Gfi1 is a critical cell-intrinsic modulator of DC versus macrophage development  
To further elucidate the mechanism of decreased DC differentiation and –function, DC 
differentiation assays in vitro were performed. Lineage-depleted hematopoietic progenitor 
cells from Gfi1-/- and Gfi1+/+ mice were incubated in the presence GM-CSF or Flt3L, two 
cytokines controlling DC differentiation. Interestingly, in contrast to Gfi1+/+ progenitor cells, 
neither GM-CSF nor Flt3L induced DC differentiation in Gfi1-/- progenitor cells. Instead, in 
conditions classically permissive for DC differentiation, Gfi1-/- progenitor cells differentiated  
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Figure 4.3.4.5. Deficient antigen presentation 
in Gfi1-/- DCs in-vivo. Gfi1+/+ and Gfi-/- mice 
were  transplanted i.v. with ova specific T 
cells(OT-II)  and   subsequent subcutaneous 
immunisation of ova albumin protein. Ova 
specific T (OT-II) cell proliferation was measured 
based on the relative FACS profile and total 
number of cells . 
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Figure4.3.5.1. Cell surface markers of 
hematopoietic progenitor cells differentiated in 
the presence of GM-CSF and IL-4.  
(a) Lineage-depleted hematopoietic progenitor cells 
from Gfi1+/+ mice and Gfi1-/- mice were assessed for 
expression of characteristic DC markers on day 8 of 
culture. Shaded histograms represent isotype 
fluorescence. The marker profile of differentiated 
Gfi1+/+ cells is typical of DCs, whereas the marker 
profile of Gfi1-/- is characteristic of macrophages.  
(b) Contour plot of GM-CSF differentiated cells 
showing CD11c+, CD11b+, F4/80+ DCs generated 
from Gfi1+/+ progenitor cells and CD11c-, CD11b+, 
F4/80+ macrophages generated from Gfi1-/-
progenitor cells. 
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into macrophages, as assessed by immunophenotype (Fig.4.3.5.1.a & b), morphology ( Fig. 
4.3.5.2.a), and capacity to stimulate allogeneic T-cell proliferation ( Fig. 4.3. 5.2.b ). Since 
Gfi1-/- myeloid cells show an enhanced production of cytokines and since IL6 has been 
described to direct macrophage over DC development in human cells, it was reasoned that this 
diverted development might be secondary to the cytokine milieu in culture. However, 
supernatants from in vitro differentiation assays did not have any effect on DC differentiation 
of Gfi1+/+ progenitor cells (data not shown), suggesting that the deficiency of Gfi1-/- cells to 
develop into DC is a cell-autonomous feature. The data of these experiments suggest that Gfi1 
is a crucial factor for the lineage determination of DC versus macrophages. 
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Figure 4.3.5.2. Characterisation of Gfi1-/-BM 
cells  differentiated in vitro. 
(a) Phase contrast image of progeny cells derived 
from lineage-depleted bone marrow cells cultured in 
the presence of GM-CSF/IL-4. Original 
magnification  x 100. 
(b) Allogeneic T cell response elicited by Gfi1+/+
and Gfi1-/- stimulator cells, respectively. Lineage-
depleted bone marrow cells were cultured in the 
presence of GM-CSF/IL-4 for 8 days.  
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4. 3.6 Retroviral mediated complementation of Gfi1 restores DC differentiation potential 
of Gfi1-/- BM cells 
In vitro differentiation studies of Gfi1-/- BM cells suggest that the defective DC differentiation 
might be a cell intrinsic feature. This notion was further confirmed by complementation 
experiments using Gfi1 encoding retroviruses. The retroviral plasmids encoding Gfi1 cDNA 
was constructed by amplifying the cDNA from the plasmid p-CMV-Gfi1 (kindly provided by 
Prof.Tarik Möröy) by PCR. The amplified PCR fragment was then subcloned into the Topo 
2.1 T-plasmid. The Gfi1 cDNA was released by digesting the Topo-Gfi1 subcloning plasmid 
with Not I and cloned into the NotI site of SFb91 –IRES-EGFP retroviral plasmid (kindly 
provided by Prof. Christopher Baum,). Figure 4.3.6.1 outlines the cloning strategy followed 
for constructing SFb91 Gfi1–IRES-EGFP retroviral plasmid.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Not I 
Figure4.3.6.1. Cloning stratergy of  Sfb91-Gfi1-IRES-EGFP-WPRE.  
(a) Gfi1 cDNA was PCR amplified using  pCMV-Gfi1 plasmid  as a template with a 5’ NotI flanking sites. The 
1272 bp amplicon was cloned into Topo 2.1 subcloning vector.  
(b)Then the Gfi1 cDNA was released  from Topo-Gfi1 plasmid by digesting with  NotI and then cloned into the 
NotI site of  Sfb91 -IRES-EGFP-WPRE to get the final  Sfb91-Gfi1-IRES-EGFP-WPRE retroviral construct. 
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The pseudotyped retroviral particles were produced by transfecting 293 gpg packaging cells 
with the respective retroviral plasmids. Sca-1+lin- hematopoietic progenitor cells from Gfi1-/- 
mice were isolated and transduced with either a retrovirus encoding the marker gene GFP 
(SFb91-GFP) or a bicistronic retrovirus encoding Gfi1 and GFP (SFb91-Gfi1-IRES-GFP). It 
was noted that a significant loss of viability of the transduced cells upon Gfi1 gene transfer, 
presumably secondary to non-physiological levels of retrovirus-mediated Gfi1 expression. 
However, in the surviving cells, 18% showed expression of the DC marker CD11c, 
suggesting a partial reconstitution of DC development in vitro (Fig. 4.3.6.2.a). We also 
addressed reconstitution of the DC development upon transplantation of retrovirus-transduced 
HSC in vivo. Sca-1+lin- HSC from  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.6.2  Reconstitution of DC development upon retroviral gene transfer.  
(a) Bone marrow progenitor cells  of Gfi1-/- mice were transduced with retroviruses encoding GFP (left panels) 
and Gfi1GFP (right panels), respectively. Cells were then differentiated in the presence of GM-CSF. On day 8 of 
culture, GFP positive cells (upper panels) were gated (G1) and CD11c-expression (lower panels)  was analysed 
by flow cytometry.(b) For in vivo reconstitution assays, Sca-1+lin- cells from Gfi1-/- mice (CD45.2+) were 
transduced with retroviruses encoding either GFP (left panels) or Gfi1-GFP (right panels) and transplanted  into 
irradiated (4.5 Gy) congenic recipient mice (CD45.1+). GFP-positive splenocytes of recipient mice were gated 
(G2)  analysed for CD11c expression  (lower panels). 
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Gfi1-/- mice were transduced either with SFb91-Gfi1-IRES-GFP or SFb91-GFP and 
transplanted into irradiated recipient mice. Upon reconstitution of the hematopoietic system,  
the mice were sacrificed and analysed for DC reconstitution. Compared to mice transplanted 
with GFP-expressing progenitor cells, it was determined that the percentage of CD11c+ cells 
among GFP-positive cells was significantly higher in mice that had received Gfi1-transduced 
progenitor cells (4.8%) compared to mice that had received GFP-transduced progenitor cells 
(0.2%, Fig. 4.3.6.2.b), suggesting that the retrovirus mediated expression of Gfi1 corrected the 
defect of DC development 
 
 
4. 3. 7. Deficient DC development in Gfi1-/- mice is associated with decreased STAT3 
activation in progenitor cells 
Previous in vitro data have shown that Gfi1 interacts with PIAS3, a known inhibitor of 
STAT3 (Rodel et al., 2000). STAT3 has recently emerged as an important mediator of DC 
differentiation. Based on the previous studies it was hypothesized that altered STAT3-
signalling may influence the developmental pathway of macrophage versus dendritic cell 
development. To investigate the activation status of STAT3 during DC differentiation, Lin- 
hematopoietic progenitor cells from Gfi1+/+ and Gfi1-/- mice were isolated and cultured in the 
presence of GM-CSF. Cells were harvested at hour 0, 30 min, and 4 hour after GM-CSF 
stimulation and the cytoplasmic and nuclear proteins were isolated. STAT3 activation upon 
GM-CSF stimulation in Gfi1-/- and Gfi1+/+ hematopoietic cells was assessed by Western blot 
analysis, comparing cytosolic and nuclear protein fractions. Whereas the specific band 
corresponding to STAT3 protein in the cytosol was comparable in Gfi1-/- and Gfi1+/+ cells 
(Fig. 4.3.7.1-top panel), a significant reduction of STAT3 in the nuclear protein fraction at all 
time points was documented (Fig. 4.3.7.1- bottom panel), suggesting that the transnuclear 
shift of activated STAT3 was impaired in Gfi1-/- cells.  
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This was further confirmed by electrophoretic mobility shift assays (EMSA), which revealed 
a significant reduction of STAT3 homo- and heterodimers in Gfi1-/- cells (Fig. 4. 3.7.2.a). 
Oct-1 specific EMSA confirmed the equal amount of protein loaded in each lanes. 
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Figure 4.3.7.1. Decreased  STAT3 
translocation in the nucleus. 
Lin-depleted bone marrow cells from 
Gfi1+/+ and Gfi1-/- mice were incubated in 
the presence of GM-CSF and IL-4. 
Cytosolic (upper panels) and nuclear 
protein fractions (lower panels) were 
purified at indicated time points. STAT3 
was detected by western blot using a 
STAT3-specific monoclonal antibody. 
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Figure 4.3.7.2. Decreased  STAT3 translocation in the nucleus.  
(a) Nuclear proteins were incubated with 32P-labeled consensus sequence oligonucleotides (h-SIE) 
recognizing STAT3 protein and subjected to electrophoresis and autoradiography.  
(b) To confirm equal loading, nuclear proteins were incubated with OCT1-specific oligonucleotides  
and subjected to electrophoresis and autoradiography. 
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the OCT1  (Fig. 4.3.7.2.b.)  Specificity of protein-DNA interaction was proven by supershift 
assays (Fig. 4.3.7.3.a) and competition assays using excess of unlabelled oligonucleotides 
(Fig. 4.3.7.3.b). Thus it was concluded that the Gfi1 deficiency and defective DC 
differentiation were associated with impaired, GM-CSF induced STAT3 signalling in 
hematopoietic progenitor cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 In summary, the results of this study convincingly demonstrate that Gfi1 plays a vital role in 
DC development and maturation. In the absence Gfi1, dendritic cells of all described lineages, 
except the Langerhans cells, are affected both qualitatively and quantitatively. Preliminary 
studies on the signal transduction pathways of Gfi1 suggest that Gfi1 might control DC 
development through STAT3 signalling. 
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Figure4.3.7.3. Competition and   supershift assays. 
(a)  Competition assay. Nuclear proteins were incubated 
with 32P-labeled consensus sequence oligonucleotides (h-
SIE)  either in the presence or absence of 100 fold 
unlabelled (cold) oligo recognizing STAT3 protein and 
subjected to electrophoresis and autoradiography.  
(b) Supershift assay. Nuclear proteins were pre-incubated 
with STAT3-specific monoclonal antibodies or mouse 
IgG1 isotype control antibodies before reaction with 32P-
labeled STAT3-specific oligonucleotides. The complexes 
were resolved on a polyacrylamide gel and subjected to 
autoradiography.  
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5. Discussion 
5.1 Transcription factor controlled differentiation of dendritic cells  
The very aim of the current study was to increase the understanding of the molecular 
complexity of the differentiation program of dendritic cells from hematopoietic progenitor 
cells. In the past few years, a series of reports have been published regarding the gene 
expression profile of dendritic cells. However, most of these studies attempted to unravel the 
genes that are involved in the maturation process of dendritic cells either in response to 
various pathogens or in response to various stimuli. Several independent approaches have 
been adopted in these studies such as serial analysis of gene expression, (SAGE; Hashimoto 
SI et al., 2000), microarray studies (Granucci F et al., 2001; Matsunaga T et al., 2002; 
Messmer D et al., 2003), combined cDNA subtraction and microarray approaches (Ahn J H et 
al., 2002), and an integrated genomic and proteomic approaches (Richards J et al., 2002; La 
NF et al 2001).   
In addition to the reports on genes involved in DC maturation, a few reports also focused on 
gene expression during DC differentiation from human monocytes (Angenieux C et al., 2001; 
Hashimoto S et al., 1999). Some pilot studies were also performed to study the differentially 
expressed genes in dendritic cells during the development from human CD34+ cells (Fisher M 
et al., 1999; Ju xs et al., 2003) and from mouse spleen derived long-term cultures (LTC; 
Wilson H et al., 2003). 
A recent report by Fohrer et. al has focused on the transcription factors, RelB and PU.1, to 
trace the lineage origin of human thymic dendritic cells and has categorised thymic dendritic 
cells into myeloid and plasmocytoid lineages based on the differences in the expression 
profiles of these transcription factors (Fohrer H et al., 2004).  
Even though most of the reports focus on identifying the genetic control of DC differentiation 
and maturation on a global level, to date, a comprehensive knowledge about the role of 
transcription factors in DC development is still lacking. This lack of knowledge could be 
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explained by the difficulties in obtaining hematopoietic stem cells and to culture dendritic 
cells in-vitro. To circumvent these technical limitations, the present study has set out to 
generate an in vitro DC differentiation system based on a novel cell line CR1-mix. 
A pioneering study on transcription factor based DC development has been recently reported 
by Hacker et al (2003). Even though their studies have identified transcription factors 
involved in DC differentiation and established the role of the transcription factor Id2 in DC 
development, their studies primarily utilised DCs derived from human CD34+ cells. In 
addition, this study was based on a direct comparison on the gene expression profiles between 
the progenitor cells and differentiated dendritic cells. In contrast, the present study differs 
from their work in the following aspects. Firstly, the present study utilised a murine 
hematopoietic DC culture system for the gene expression studies. Secondly, this work focused 
on the transcription factors that were upregulated during the early pathways of DC 
differentiation. Hence, this study for the first time deciphers the role of transcription factors 
that control the early pathways of dendritic cells. 
 
5.2 DCs differentiated from FDCP-mix cells have considerable proportion of 
‘contaminating’ granulocytes and macrophages 
To establish a cell system that allows the molecular analysis of DC differentiation with an 
emphasis on transcription factors, the initial work was done in 32D cells. 32D cells are 
originally described by Valtieri et al (Valtieri M et al, 1987) as a murine, hematopietic, IL3 
dependent cells. Even though the differentiation potential of these cells across granulocytic 
and macrophage lineages (Ramos G, 2004) has been demonstrated, their ability to 
differentiate into DC lineage has not been explored so far. Thus the present study aimed to 
differentiate these cells into DC lineage.  In spite of culturing these cells under various culture 
conditions, successful results could not be obtained. The failure of these cells to differentiate 
into DCs could be explained either by their loss of potential to differentiate into DCs or by the 
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unusual chromosome instability phenomenon (Agliano AM et al, 2000) reported previously in 
this cell line. 
Another hematopoietic cell line, FDCP-mix was used in this study. FDCP-mix cells were 
established by infecting the long-term bone marrow cultures with src virus (Just U, 1991). 
FDCP-mix cells are IL-3 dependent, multipotent hematopietic progenitor cells. Previous 
studies have shown that FDCP-mix cells can be differentiated into granulocytes, macrophages 
(Ford AM,1992), erythrocytes, megakaryocytes, and early B-lymphoid lineage cells in vitro 
(Spooncer et al., 1986; Just et al, 1991; Ford et al, 1992). Recently Schroeder T, et. al (2000) 
have documented the differentiation potential of FDCP-mix into dendritic cells (Schroeder T., 
2000). However in the present studies it was observed that the DCs that were obtained from 
FDCP-mix cells, in the presence of GM-CSF, were quite heterogeneous due to the 
‘contaminating’ granulocyte and macrophage populations: Hence it was inevitable to define a 
novel differentiation system which might allow us to obtain synchronised and homogeneous 
DC population.  
 
5.3 Retroviral mediated overexpression of the intracellular domain of Notch1 generates 
a novel IL3 dependent hematopoietic progenitor cell line 
To date several approaches have been used to immortalize and expand hematopoietic 
progenitor cells. Retrovirus mediated overexpression of genes such as MDR1 (Bunting KD et 
al., 1999), Src (Just U et al 1991), gp130 (Audet j et al 2001), TEL-AML1 (Morrow M et al., 
2004), and myeloid lysozyme gene (Ye M et al., 2003) and transcription factors such as 
Notch1 (Varnum F et al., 2000), Hox B4 (Antonchuk J et al., 2002;), ß-catenin (Reya T et al., 
2003) and Lhx2 (Pinto O P et al., 2002) have been reported in the literature. 
However, none of these cell lines has been reported to have DC differentiation potential. The 
present study made use of the technology initially reported by Varnum-Finney and colleagues 
(2000). These investigators have generated a retrovirus encoding the intracytoplasmic domain 
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of notch1 (ICN) to immortalize hematopoietic stem cells (Varnum F, 2000). In contrast to 
their approach, the present study modified the strategy in various aspects.  Firstly Varnum-F 
al have shown that the overexpression of ICN immortalizes hematopoietic cells. However, 
these investigators did not check ICN transduced cells for their dependency on individual 
cytokines. In contrast, the present work examined the dependency of ICN transduced cells on 
the individual cytokines of the stem cell cytokine cocktail (IL-3, IL-6, Flt3L, SCF) and 
concluded that IL-3 plays a major role in the viability of these cells. Secondly, their goal was 
not to generate a hematopoietic cell line from the ICN transduced cells. In contrast, our 
purpose was to generate a hematopoietic cell line. CR1-mix cells showed a normal karyotype 
and could be maintained in culture for more than 2 years by repeated thawing and freezing. 
Thirdly, this study has shown that  CR1-mix cells could be differentiated into dendritic cells.  
From the transplantation studies it was observed that CR1-mix cells did not provide efficient  
radioprotection to lethally irradiated mice. Nevertheless, their in vivo differentiation potential 
into most of the hematopoietic lineages such as dendritic cells, T cells, B cells, NK cells, 
granulocytes and macrophages except erythrocytes is documented in sublethally irradiated 
mice. The failure of CR1-mix cells to protect the lethally irradiated mice from radiation 
damage could be explained by the inability of these cells to differentiate into erythrocytes, 
despite its potential to generate all the other hematopoietic lineages. Moreover, 
immunophenotypic studies  conducted in this cell line provided an evidence that this cell line  
expresses most of the hematopoietic stem/progenitor cell markers and lack the expression of 
surface markers that indicate a specific hematopoietic lineage. 
Taken together, the present study suggests that CR1-mix cells may be considered as an 
immature multipotent progenitor cell line. 
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5.4 CR1-mix- a novel tool to study both myeloid and plasmocytoid dendritic cell 
development 
In the past, several other cell lines with DC features have been described (Paglia et al., 
1993;Girolomoni et al, 1995; Xu et al, 1995; Rasko et al, 1997, Schroeder T et al, 2000). 
However, these cell lines differ from CR1-mix in various aspects. Some of these cell lines 
were frozen at one stage of DC development; some others are tumorigenic or transformed by 
an oncogene, while the others have an ‘improper’ DC phenotype.  Examples include the 
tumorigenic and factorindependent IGM36 cell line, derived from a GM-CSF transgenic 
mouse (Rasko et al, 1997), the immature skin-derived DC cell line- FDSC (Girolomoni et al, 
1995), the immature spleen derived CB1 cell line (Paglia at al, 1993) and the FDCP-mix cells 
(Schroeder et al 2000). On the other hand none of these cell lines has been shown to 
differentiate equally into both myeloid and plasmocytoid dendritic cells in vitro. Interestingly, 
the data of this study indicate that CR1-mix cells can efficiently differentiate into both 
myeloid and lymphoid dendritic cell lineages in a directed and synchronous manner both in 
vitro and in vivo.  
In addition, the morphology, immunophenotype and functional properties such as IL-12 
secretion and allogenic T cells proliferation capacity of the CR1mix cells resemble bone 
marrow derived primary dendritic cells. These features along with the karyotypic stability 
make the cell line a versatile tool for analysing molecular and biochemical events associated 
with determination, differentiation and maturation of the different dendritic cell lineages.    
 
 
5.5   The transcriptional repressor Gfi1 is critically important for DC development 
Using a transcriptional screening approach, Gfi1 was identified as a crucial transcription 
factor controlling DC-development and -function. Gfi1 is a transcriptional zinc finger 
repressor originally identified as a target gene for proviral insertions leading to IL2 
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independent growth in a T cell lymphoma line (Gilks et al., 1993). Gfi1 contains six C2H2 
zinc fingers and a transcriptional repressor domain (SNAG) (Grimes et al., 1996). Previous 
studies suggest that Gfi1 acts as a protooncogene by accelerating T-cell proliferation and 
inhibiting apoptosis and cell cycle arrest (Grimes et al., 1996; Karsunky et al., 2002a; Schmidt 
et al., 1998). Furthermore, Gfi1 regulates proliferation and differentiation of thymic T-cells 
(Yucel et al., 2003). More recently, an intrinsic role of Gfi1 in granulocyte development has 
evolved, when the analysis of Gfi1-/- revealed an unexpected absence of mature neutrophils 
(Hock et al., 2003; Karsunky et al., 2002b). Heterozygous mutations in Gfi1 have been 
identified in rare patients with hereditary neutropenia, suggesting that dominant negative 
variants may block neutrophil differentiation (Person et al., 2003). The present study provides  
evidence for yet another role of Gfi1 in controlling the complexity of hematopoietic stem cell 
differentiation: Gfi1 deficiency leads to a global reduction in the number of DC precursors 
and their progeny in bone marrow, thymus, spleen and lymph nodes, as well as to incomplete 
DC maturation and function. Furthermore, Gfi1 appears to be key regulator of DC versus 
macrophage development.  
 
5.6 Gfi1 kncokout mice show reduced DC numbers of myeloid, lymphoid and 
plasmocytoid lineages except Langerhans cells 
The initial aim of this study was to identify transcription factors controlling specific subsets of 
DCs, in particular in the development of “myeloid” DCs as progeny of GM-CSF treated HSC. 
Previous reports have implicated a role for PU. 1(Anderson et al., 2000; Guerriero et al., 
2000), RelB (Wu et al., 1998), and Ikaros C (Wu et al., 1997) in the differentiation of 
CD11c+CD8a- “myeloid” DCs. Unexpectedly, a global reduction of all DCs in primary and 
secondary lymphoid organs in Gfi1 deficient mice was observed in this study, irrespective of 
CD8a expression. Although these data do not exclude the existence of “myeloid” DCs, the 
analysis of Gfi1-/- mice does not provide any evidence for a distinct myeloid DC lineage. 
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Interestingly, Gfi1 deficiency did not perturb Langerhans cell development. In that respect, 
Gfi1-deficient mice resemble RelB-/- (Wu et al., 1998) and IkarosC-/- mice (Wu et al., 1997) 
that are characterized by a deficiency of CD8a- DCs while epidermal LC appear normal. In 
contrast, TGFb-/- (Borkowski et al., 1996) and Id2-knockout mice (Hacker et al., 2003) show 
a complete lack of epidermal LCs, while other DC subpopulations are at least partially 
preserved, supporting the notion of a distinct LC lineage. Thus, the analysis of Gfi1-/- 
deficient mice provides additional evidence for a dissociation of DC development in 
peripheral lymphoid organs and epidermal Langerhans cells.  
 
5.7 Gfi1 plays a crucial role in determining the lineage outcome between dendritic cells 
and macrophages 
The decisive factors controlling macrophage versus DC development remain elusive. Various 
cytokines, such as IL6, TNFa, and interferon-g induce DC versus macrophage differentiation 
in vitro (Chomarat et al., 2000; Chomarat et al., 2003; Delneste et al., 2003). Other studies 
suggest that the notch ligand delta-1 inhibits macrophage differentiation while permitting DC 
differentiation (Ohishi et al., 2001). However, analysis of cytokine knockout mice has not yet 
revealed any specific factor that dissociates DC and macrophage development. Intracellular 
mechanisms responsible for DC versus macrophage development are currently not known. 
The phenotype of Notch-1-/- mice suggests that both DC and LC development is completely 
independent of Notch-1 (Wilson et al., 2001). In mice doubly deficient for two NFkB subunits 
(p50-/-RelA-/-), GM-CSF-dependent DC development is severely reduced whereas M-CSF 
dependent macrophage development appears normal (Ouaaz et al., 2002). In the undertaken 
study, both Flt3L and GM-CSF, two cytokines inducing DC development in wildtype 
hematopoietic stem cells, drive Gfi1-/- hematopoietic progenitor cells into macrophage 
differentiation. Thus, Gfi1 is a unique factor governing DC versus macrophage development 
in vitro. Previous reports have identified an excess of atypical “immature” myeloid cells in 
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Gfi1-/- mice, characterized by expression of Gr1 and Mac1 (Hock et al., 2003; Karsunky et al., 
2002b). Hock et al. proposed a dual function of Gfi1, which may be required not only for 
neutrophil maturation but also for terminal macrophage differentiation (Hock et al., 2003). 
We have shown that the absence of Gfi1 leads to a significant reduction in HSC, CLP, CMP 
and DC progenitor cells while GMPs are increased in numbers, suggesting that Gfi1 acts on 
multiple levels of progenitor cell differentiation, including critical checkpoints of DC versus 
macrophage development (Fig. 5. 7.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.8 Gfi1 controlled DC differentiation is dependent on  STAT3 activation 
Mechanistically, the function of Gfi1 is under active investigation. Gfi1 shares the same DNA 
binding- and a SNAG (Snail and Gfi1 family of proteins) repression domain with its 
homologue, Gfi1B. Both factors have redundant and unique biological roles in controlling 
hematopoiesis. As a transcription factor, Gfi1 displays activity in the nucleus. In addition 
there is evidence for a potential cytoplasmatic role for Gfi1 mediated by physical interaction 
with PIAS3 (protein inhibitor of activated STAT3), a specific inhibitor of STAT3. Using a 
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Figure 5..7.1 Proposed Gfi1 dependent checkpoint in DC development  
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STAT3-dependent reporter gene assay, earlier studies have suggested that Gfi1 can increase 
STAT3 signalling by overcoming the inhibitory effects mediated by PIAS3 (Rodel et al., 
2000). The present study confirms and extends this observation in a functional model of DC 
differentiation and provide unequivocal evidence that in the absence of Gfi1, STAT3 
signalling is significantly reduced in early hematopoietic progenitor cells. Further evidence 
for a critical role of STAT3 in DC development has recently been proposed by Laouar et al. 
(Laouar et al., 2003). Their studies determined STAT3 activation as a critical checkpoint of 
Flt3L regulated DC development. In the absence of STAT3, the transition of CLP and CMP to 
Flt3+ DC precursors was severely impaired, while GM-CSF-induced DC differentiation in 
vitro was not altered in this system. In contrast to the complete deficiency of STAT3, in the 
absence of Gfi1, both Flt3L and GM-CSF-dependent DC differentiation is abrogated, 
suggesting that deficient STAT3 signalling is not the only mechanism explaining the 
phenotype of Gfi1-/- hematopoiesis.  These differences could either be explained by residual 
STAT3 activation in Gfi1-/- cells or the effects of multiple STAT3 isoforms present in DC 
development (Welte et al., 1997). Furthermore, Gfi1 acts as a transcriptional modulator and 
influences a multitude of downstream factors. The identification of downstream targets 
illustrates the complexity of Gfi1-dependent pathways. Gfi1 binds to functionally diverse sets 
of genes in myeloid cells such as JAK3, IL8, c-myc and members of the C/EBP family (Duan 
and Horwitz, 2003). Interestingly, Gfi1 also represses its own transcription in vitro (Doan et 
al., 2004; Duan and Horwitz, 2003) and in vivo (Yucel et al., 2004). The observation of 
fluctuating Gfi1 expression and untoward toxic effects of retrovirus-mediated Gfi1 expression 
in the present work, reflect the importance of tight transcriptional regulation of Gfi1 gene 
expression in DC precursor cells. 
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5.9 Gfi1 controls both development and activation of dendritic cells 
 Previous reports have differentiated DC maturation and DC activation as molecularly distinct  
events, phenotypically characterized by upregulation of surface expression of MHC class II 
and the costimulatory molecules CD40, CD80 and CD86 and production of inflammatory 
cytokines (e.g. IL12) (Kaisho and Akira, 2001; Kobayashi et al., 2003; Ouaaz et al., 2002). 
DC maturation is primarily induced upon signalling via Toll-like-receptors (TLR) and CD40. 
Gfi1-/- DCs show decreased expression of MHC class II and decreased upregulation of 
costimulatory receptors upon stimulation with LPS and anti-CD40 monoclonal antibodies, a 
phenotype consistent with impaired DC maturation. TRAF6 has emerged as a point of 
convergence for both TLR- and CD40-mediated signalling cascades, linking both pathways to 
NFkB activation. TRAF6-/- deficient DCs show decreased maturation and thus resemble Gfi1-
/- DCs (Kobayashi et al., 2003). However, in contrast to Gfi1-/- DCs, TRAF6-/- DCs are 
characterized by decreased cytokine production (Kobayashi et al., 2003). The analysis of mice 
deficient for the expression of defined factors regulating NFkB have provided more insights 
into the complex network regulating DC activation and cytokine production. For example, 
mice doubly deficient in the NFkB subunits p50 and RelA exhibit a severe reduction in CD8+ 
and CD8- DCs, while mice doubly deficient in p50 and cRel show impaired CD40L-mediated 
survival and IL12 production (Ouaaz et al., 2002). Furthermore, DCs from mice deficient in 
the negative NFkB regulator NFkB2 show enhanced expression of activation markers but 
produce normal levels of cytokines (Speirs et al., 2004). In contrast to these models however, 
Gfi1-/- deficient DCs reveal a dissociated phenotype characterized by decreased maturation 
and increased activation. In view of these results documenting decreased STAT3 activation in 
DC progenitors, it is tempting to speculate that the increased cytokine secretion is related to 
deficient STAT3 activation in DCs. Targeted STAT3 deficiency in the hematopoietic system 
is associated with chronic enterocolitis, aberrant inflammation and lethality to septic 
peritonitis (Matsukawa et al., 2003; Takeda et al., 1999; Welte et al., 1997). This pathology is 
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associated with increased expression of inflammatory cytokines. No data has been published 
about maturation of STAT3-/- DCs, but overstimulated innate immunity is associated with 
enhanced NFkB activity in STAT3-/- hematopoietic cells (Welte et al., 2003). Thus Gfi1-/- 
mice offer a model system to further dissect the mechanisms controlling DC maturation and 
activation. Recent data suggest a PIAS3-dependent negative regulation of the p65 subunit 
(RelA) of NFkB and thus establish a potential link between STAT3 and NFkB pathways 
(Jang et al., 2004). Further studies are required to elucidate the significance of this potential 
crosstalk. 
 
In conclusion, results of this study demonstrated a key role for the transcriptional repressor 
Gfi1 in DC development and function. These studies also provide insights into the complex 
hierarchical network controlling DC differentiation, maturation and activation, and reveal 
specific pathways that might ultimately be important for the design of rational DC therapies. 
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